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1 Introduction 
1.1 The hypoplastic left heart syndrome 
1.1.1 Definition, epidemiology and historical background 
Tchervenkov used the hypoplastic left heart syndrome (HLHS)  as a generic term to describe 
“a spectrum of malformations characterised by severe underdevelopment of the left heart-aorta complex, 
consisting of mitral and/or aortic valve [AV] atresia, stenosis or hypoplasia with marked hypoplasia/absence 
of the left ventricle [LV] and hypoplasia of the ascending aorta and the aortic arch” (Cox and Wilson 
2007). HLHS is one of the most severe and complex congenital heart diseases (Bradley 1999). 
It encompasses a hypoplasia of the aortic and the mitral valve and varying degrees of left-
ventricular hypoplasia. Because of a broad spectrum of possible anatomic variations, a 
differentiation between a severe form of HLHS, which encompasses an atresia of the AV 
and mitral valve combined with a non-existent LV, and a milder form, which is termed 
hypoplastic left heart complex, is commonly used (Tchervenkov et al. 2006).  
HLHS is a lethal disease that necessicates therapeutical interference. Accounting for 
25% of all CHD mortalities, HLHS is the leading cause of death in infants under the age of 
one year (Samánek et al. 1988; Gillum 1994; Bradley 1999). Roger and colleagues stated that 
HLHS amounts to 4-8% of all cardiovascular malformations (Roger et al. 2011), which is 
consistent with the findings of Bradley, who proclaimed it accounts for 3.8% of all CHD 
(Bradley 1999; Risebro and Riley 2006). Sokolowski and colleagues claimed HLHS to amount 
to 9.1% of prenatally diagnosed CHD (Sokolowski et al. 2019). According to the Baltimore-
Washington infant study, the incidence is estimated to 0.16-0.27 per 1000 live births (Ferencz 
et al. 1985). Samánek and colleagues presented data about the apportionment of age at death 
of patients who suffer from HLHS without treatment. Most patients (89%) died within the 
first month of life and 100% had died by the age of ten months (Samánek et al. 1988). 
Compared to this, Noonan and Nadas published differing data years in advance, where the 
majority (82%) of infants died by the age of three months (Noonan and Nadas 1958).  
The first case of aortic atresia, which was approved to be one morphological feature 
of HLHS several years later, was reported by Canton in the year 1849, who gave a brief 
narration about pathological findings (Gehrmann et al. 2001). In 1851, the pathologist 
Bardeleben published a report about an “obliteration of the left ostium arteriosum in the heart of a 
1 Introduction 8 
half-year-old infant“, which included a description about the pathophysiology, anatomical 
malformations, etiological notions and the clinical manifestations of this disease that  found 
its final naming only 107 years later (Gehrmann et al. 2001). Then, in the year 1958, the 
pediatric cardiologists Noonan and Nadas were the first authors to use the term HLHS that 
decribes a variety of structural cardiac anomalies, which share the common feature of an 
underdevelopment of the left heart-aorta complex (Noonan and Nadas 1958). Even though 
the term HLHS did occur for the first time in 1958, it was Lev in the year 1952, who first 
described a series of hearts with an underdevelopment of the LV and an aortic tract 
hypoplasia, who referred to it as hypoplasia of the aortic tract complex (Lev 1952). 
1.1.2 Diagnosis and clinical presentation 
Systematic screening for cardiac aberrancies with means of fetal echocardiography enables 
the prenatal diagnosis of HLHS from as soon as the second trimester of pregnancy 
(Sokolowski et al. 2019). This positively affects postnatal survival rates (Beroukhim et al. 
2015). The assessment of the cardiovascular status and hemodynamical parameters facilitates 
a severity stratification that directly implies peri- and postnatal treatment strategies, which 
differ in the degree of therapeutical urgency (Sanapo et al. 2017). Different authors proposed 
divergent classification systems, such as the emergency neonatal cardiac intervention (Pruetz 
et al. 2014), the level-of-care groups (Donofrio et al. 2015) or a three-group-based system 
proposed by Sokolowski (Sokolowski et al. 2019). They all tend to facilitate clinical decision 
making for treating HLHS patients. Sokolowski and colleagues collated prenatally diagnosed 
HLHS patients to three groups. The first group (severest HLHS) of highest urgency, with 
the severest clinical manifestations, necessitates immediate intervention. The second group 
(severe urgent HLHS) of severe urgency requires cardiac catheterization within 24 hours. In 
the third group (severe planned HLHS) neonates prove to be relatively stable (Sokolowski et 
al. 2019). For those HLHS patients that may be related to the third group, the clinical 
presentation can be asymptomatic at time of birth. Often, no signs of profound cyanosis, 
respiratory distress or an irregular APGAR score (acronym for appearance, pulse, grimace, 
activity and respiration) can be found (Noonan and Nadas 1958; Feinstein et al. 2012). Those 
HLHS patients that prenatally show echocardiographical signs of the severest cardiac 
impairments are assigned to the first group, where perinatal delivery is marked by rapid 
clinical deterioration within minutes to hours (Sokolowski et al. 2019).   
Not every HLHS patient is prenatally diagnosed (Feinstein et al. 2012). Postnatal 
physical examination tightly correlates with the pathophysiology of HLHS. The right 
ventricle (RV) underlies a volume overload, which results in compensatory enlargement of 
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the heart because of dilation and hypertrophy. Roberts and colleagues described right-
ventricular hypertrophy in 46% of patients (Roberts et al. 1976). At palpation of the chest, a 
prominent right ventricular impulse and decreased or absent peripheral pulses often become 
apparent (Watson and Rowe 1962). Roberts and colleagues found a soft nonspecific, systolic 
ejection murmur over the left sternal border to be auscultatorily audible, which occurs 
because of turbulent blood flowing through a constricting ductus arteriosus (DA; Yun 2011). 
Watson and colleagues explained the occurrence of a holosystolic murmur on the sternal 
border, which is consistent with tricuspid valve regurgitation, with proceeding dilation of the 
RV attended by an annular dilation (Watson and Rowe 1962). Furthermore, clinical signs of 
a pulmonary overcirculation may become apparent as tachypnea, hepatomegaly and gallop 
rhythm (Connor and Thiagarajan 2007). An aggravating tachypnea may also be a sign for 
compensation of the metabolic acidosis, which in turn represents a disturbance of the cardiac 
output (Moodie et al. 1972; Lloyd et al. 1986; Hebra et al. 1993; Kern et al. 1997; Tabbutt et 
al. 2001; Tworetzky et al. 2001; Stieh et al. 2006; Feinstein et al. 2012).  
Transthoracic echocardiography represents the gold standard of diagnostic 
modalities, which offers a positive predictive value of 96-100% in some centers (Chang et al. 
1991; Stümpflen et al. 1996; Bravo-Valenzuela et al. 2018). The parasternal long axis and the 
apical four-chamber view enable the evaluation of the mitral valve and AV. In case of aortic 
atresia, the flow pattern in the ascending aorta might be retrograde (Connor and Thiagarajan 
2007; Yun 2011; Feinstein et al. 2012; Bravo-Valenzuela et al. 2018). The suprasternal and 
high parasternal view enable the assessment of the aortic morphology. Furthermore, the 
apical four-chamber view offers the possibility to assess the tricuspid valve and the possible 
occurrence of right-ventricular hypertrophy and dilation. The occurrence of endocardial 
fibroelastosis (EFE) can be diagnosed due to an echo-bright incidence of the left-ventricular 
endocardium (Shimada et al. 2015). Another diagnostical target is the evaluation of the truncus 
arteriosus. Its pattern of blood flow and indirect signs of pulmonary vascular resistance can 
be assessed. The evaluation of the patency and the blood-flow pattern of interatrial 
communication, which is enabled by the subcostal view, is of high therapeutical relevance 
(Yun 2011; Bravo-Valenzuela et al. 2018). The restriction degree of the atrial septal defect 
(ASD) represents a crucial point for clinical decision making. A mild restrictive degree of 
interatrial communication constitutes a beneficial state that attenuates pulmonary 
overcirculation. Immediate intervention prevents the life-threatening constellation of a 
highly restricted ASD (Atz et al. 1999; Rychik et al. 1999; Vlahos et al. 2004). Furthermore, 
low-speed perfusion across the atrial septum is a desirable condition for the postpartal period 
(Bravo-Valenzuela et al. 2018).  
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1.1.3 Treatment 
1.1.3.1 Postnatal surgical palliation 
The treatment of HLHS still is a surgical dominion. HLHS used to be a lethal illness before 
the period of operative palliation started to emerge in the 1980s (Sinha et al. 1968; Deely et 
al. 1971; Doty and Knott 1977; Knott and Doty 1977; Behrendt and Rocchini 1981; 
Norwood et al. 1983).   
1.1.3.1.1 Preoperative management 
Hemodynamical stabilization, sustainment of the patent ductus arteriosus (PDA) and retention 
of end-organ perfusion are the cornerstones of preoperative management (Tabbutt et al. 
2001; Stieh et al. 2006; Feinstein et al. 2012). The rapid decrease in pulmonary vascular 
resistance endangers circulatory balance. Pulmonary perfusion (Qp) increases at the expense 
of cardiac output (Johnson et al. 2008). The pulmonary-to-systemic-flow ratio (Qp/Qs) 
augments, where Qs represents systemic perfusion. Barnea and colleagues accentuated that 
optimal availability of systemic oxygen can be achieved by a Qp/Qs of smaller than one 
(Barnea et al. 1994). Shortly after delivery and diagnosing HLHS, an intravenous infusion of 
prostaglandin E1 is required to maintain the DA patency (Connor and Thiagarajan 2007; 
Feinstein et al. 2012). As a sign of pulmonary overcirculation, an oxygen saturation around 
90% is observed. In the pathophysiological setting of HLHS, too high parameters of oxygen 
saturation are counterproductive. It indicates that pulmonary hyperperfusion is predominant 
and the targeted aim of a circulatory balance is not established yet. Ideally, the measured 
oxygen saturation should decrease to around 80% (Tabbutt et al. 2001). Sedation, which 
leads to hypoventilation, and the inspiration of nitrogen and carbon dioxide are performed 
to increase the vascular resistance of the lungs (Shime et al. 2000; Johnson et al. 2008). 
Hypercarbia increases peripheral oxygen delivery (effect of Bohr). Ramaamoorthy and 
colleagues presented data that support the utilization of carbon dioxide over nitrogen due to 
a higher cerebral oxygenation, which results from intracerebral vasodilation because of 
hypercarbia (Ramamoorthy et al. 2002). Furthermore, Stieh and colleagues reported that the 
decrease of systemic afterload helps to prevent end-organ damage and in-hospital mortality 
by reduction of the decisive risk factor of preoperative artificial respiration (Stieh et al. 2006).  
Adjunct to prostaglandin, milrinone, sodium nitroprusside and phenoxybenzamine are often 
applied. Showing effects both inotropic and arterial vasodilating, diuretic therapy is of 
medicamentous concern, where furosemide is commonly used (Johnson et al. 2008).  
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1.1.3.1.2 Intraoperative management 
Two different therapeutical possibilities delineate the operative management of neonates that 
suffer from HLHS. A continuous contention about the better practice exists (Bailey 2004; 
Elliott 2004; Chrisant et al. 2005). On the one hand, a three-staged operation presents one 
option, which shall find further explication below. On the other hand, orthotopic cardiac 
transplantation displays an alternative, which was first performed by Bailey in the year 1985, 
where a limited disposability of the donor hearts represents a huge point of restriction (Bailey 
et al. 1985).   
The Norwood procedure represents the first stage of surgical palliation. The 
hypoplasticity of the LV impedes a proper ventricular function. Therefore, the RV is chosen 
to take over the support of systemic circulation in a mode of single-ventricle repair (Connor 
and Thiagarajan 2007). The hypoplastic ascending aorta represents a hemodynamical barrage. 
That is why, the construction of a neoaorta (NA) is required, which is compiled of the vessel 
walls of the proximal main-pulmonary artery and the ascending aorta in addition to a goretex 
mesh that is used for enlargement of the lumen of the NA (Silva et al. 2007). The 
performance of septectomy, in case no ASD exists, allows oxygenated blood to enter 
systemic circulation over the NA by an interatrial communication. A regulated Qp is aspired 
by the establishment of a so-called Blalock-Taussig shunt (BT shunt; Silva et al. 2007; 
Feinstein et al. 2012). For its construction the right-subclavian artery is connected to the 
right-pulmonary artery, where nowadays, the modified BT shunt (mBT shunt) is commonly 
applied. It uses a graft of polytetrafluoroethylene, which varies in its diameter and length, to 
connect those vessels (Silva et al. 2007; Feinstein et al. 2012). Operative alternatives are the 
so-called Sano modification and hybrid approaches. The Sano modification uses a RV-to-
pulmonary-artery conduit (Frommelt et al. 2007; Silva et al. 2007). Hybrid approaches 
combine methodical areas of interventional cardiology with cardiothoracic surgery, such as 
stenting of the PDA or banding of the pulmonary arteries (Galantowicz and Cheatham 2005; 
Murphy et al. 2015). It bears certain benefits compared to operative approaches, which 
necessitate cardiopulmonary bypass and cardioplegic arrest (Li et al. 2007).  
The second stage of operative treatment is the so-called bidirectional Glenn procedure, 
which was first drafted by Glenn in 1958. It is normally executed at the patient’s age of two 
until 18 months (Glenn 1958; Ishii et al. 2014; Wilson et al. 2018). Its main purpose lies in 
the dissipation of the aortico-pulmonary shunt and connection of the superior vena cava 
with the pulmonary artery. The aim of this stage is to prevent pulmonary overcirculation. 
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Thereby, the development of pulmonary hypertension and remodeling of the RV shall be 
avoided (Ishii et al. 2014; Chen et al. 2015).  
The so-called Fontan procedure is the third operative step, which was first applied in 
1971 to treat tricuspid atresia (Fontan and Baudet 1971). It regularly is explicated at the 
patient’s age of two until four years (Wilson et al. 2018). The ten-year survival of patients 
that undergo Fontan procedure accounts for 61%, based on a retrospective study by Pundi 
and colleagues (Pundi et al. 2015). The operative aim is to construct a cavopulmonary 
connection by linkage of the inferior vena cava to the pulmonary artery. The interposed 
conduit is fenestrated and connected to the right atrium to commute the venous flow 
(Hinton and Benson 2012). Survival rates have increased, nevertheless, cardiac arrhythmias, 
protein-losing enteropathy (PLE) and thrombembolic events are frequently observed 
complications (Pundi et al. 2015).  
1.1.3.1.3 Postoperative management 
The three-staged palliation of patients that suffer from HLHS is a mode of single-ventricle 
repair, which uses the RV to maintain systemic circulation. Management of volume and 
pressure overload of the RV marks postoperative treatment, which targets unloading of the 
right-ventricular workload (Hinton and Benson 2012). Frequent complications that occur in 
the immediate postoperative phase are hypoxemia and a dysbalance in acid-base status, which 
are crucial to be treated immediately with ventilatory assistance. Since, postoperative 
alimentation is decisive, the utilization of a nasogastric tube is indicated, if oral application is 
impossible (Hinton and Benson 2012).   
1.1.3.2 Fetal cardiac interventions 
Maxwell and colleagues first carried out fetal cardiac interventions (FCI) in the late 1980s 
(Maxwell et al. 1991; Feinstein et al. 2012). The pathomorphological sequence of an aortic 
stenosis leading to left-ventricular dilation, which secondarily promotes the occurrence of 
EFE and finally a hypoplastic LV, represents its therapeutical starting point (Danford and 
Cronican 1992; Mäkikallio et al. 2006; Selamet Tierney et al. 2007; McElhinney et al. 2009; 
Feinstein et al. 2012; Shimada et al. 2015). In this intervention, patients that were prenatally 
diagnosed with severe aortic stenosis during mid-gestation, but did not show EFE yet, 
undergo fetal aortic valvuloplasty (FAV) to reconstitute biventricular circulation. By doing 
so, the transition into HLHS is aspired to be prevented (Mäkikallio et al. 2006; McElhinney 
et al. 2009; Freud et al. 2014). FAV was aspired to become one alternative therapeutical 
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approach to postnatal surgical palliation (Freud et al. 2014). Despite growing technical 
expertise, the fetal loss from FCI accounts for 10-15% (Feinstein et al. 2012).   
1.1.4 Long-term outcome 
To point out the severity of HLHS, the long-term outcome of surgically palliated HLHS 
patients shall be presented.  Freud and colleagues stressed that long-term morbidity still poses 
a crucial challenge (Freud et al. 2014), where Feinstein and colleagues estimated that 70% of 
HLHS patients, who underwent the three-staged surgical palliation, reach adulthood with a 
consecutive decline of survival, once having reached it (Feinstein et al. 2012). The five-year 
mortality of patients with a cyanotic heart disease that were treated with Fontan procedure 
accounts for 8.2%, where 30% of those adults with Fontan circulation that die, are assumed 
to die from sudden cardiac death (Feinstein et al. 2012). Adults with Fontan circulation 
expose a reduced exercise tolerance and an elevated risk for chronic heart failure, where 10% 
exhibit a progressive heart failure NYHA class III/ IV (New York heart association 
functional classification). Frequent complications of adult HLHS patients are PLE, cardiac 
arrhythmias, hepatopathies, thrombembolism or plastic bronchitis (Feinstein et al. 2012). 
HLHS is a disease that offers no causal treatment. Despite of therapeutical 
advancements, which have been made so far, the limited long-term outcome reflects the 
necessity to invest more in better understanding of molecular mechanisms, which lead to 
HLHS, to develop new therapeutical strategies. 
1.1.5 Pathophysiology and -morphology  
HLHS is a cyanotic CHD, where systemic blood flow depends on the PDA (Cassidy et al. 
2015). It belongs to the group of the so-called left-sided obstructive lesions (Yun 2011). 
Without patency of the DA, no oxygenated blood can enter systemic circulation, which leads 
to reduced blood flow, hypoxemia, metabolic acidosis, vascular shock and finally, if 
untreated, exitus (Connor and Thiagarajan 2007; Feinstein et al. 2012). Ductal contraction 
reduces the volume of blood, which would normally be conducted from the pulmonary trunk 
to the aorta. Ductal contraction coerces the blood flow to enter pulmonary circulation. As a 
result, oxygen saturation augments (Connor and Thiagarajan 2007; Vogel et al. 2010; Yun 
2011; Tola et al. 2015). In addition, the pulmonary vasculary resistance decreases, which leads 
to an increase in pulmonary blood flow. As a result, systemic circulation is reduced and atrial 
pressure increases. Pulmonary congestion and volume overload of the RV are promoted, 
which potentially induces congestive heart failure (Connor and Thiagarajan 2007). In HLHS, 
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the LV is non-contributory to the maintenance of systemic circulation because of its 
hypoplasticity (Freedom et al. 1977; Thiene et al. 1979; Mahowald et al. 1982). The degree of 
left-ventricular hypoplasia is variable, which can range from ventricular absence to a LV of 
almost normal dimensions for the body-surface area of the patient (Kanjuh et al. 1965; 
Thiene et al. 1979; Mahowald et al. 1982; Hastreiter et al. 1983). In HLHS, the LV is 
frequently found to be associated with EFE (Lurie 2010; Shimada et al. 2015; Xu et al. 2015; 
Crucean et al. 2017; Graupner et al. 2018). Crucean and colleagues found an association 
between EFE and HLHS of 70% in 78 specimens (Crucean et al. 2017), where Graupner 
and colleagues pointed out the negative impairment of the surgical outcome of HLHS 
patients that expose EFE (Graupner et al. 2018). EFE, which is characterized by an 
endocardial broadening of elastin and collagen filaments with rarefied vascular and cellular 
components, prevents the LV from adequately responding to the growing demands of 
systemic circulation in a developing heart by left-ventricular growth retardation (Friehs et al. 
2013; Shimada et al. 2015). Shimada and colleagues gave decided evidence that EFE 
secondarily occurs as a reaction to distention in the immature LV, which then leads to 
hypocontractility of a hypoplastic LV (Feinstein et al. 2012; Shimada et al. 2015). In the year 
2015, Xu and colleagues published data, which showed that aberrant endothelial-to-
mesenchymal transition (EndMT) causes EFE suggesting molecular mechanisms leading to 
HLHS (Xu et al. 2015). EndMT is a cellular process, where endothelial cells lose their cellular 
integrity and adopt mesenchymal identity (Zeisberg and Kalluri 2010). Its relevance for 
physiological and aberrant processes of cardiogenesis will be outlined below. Another 
pathomorphological hallmark of HLHS is the hypoplasia of the ascending aorta, which is 
associated with an atresia (or a stenosis) of the AV that allows very little (or no) egress of 
onward blood flow (Bharati and Lev 1984). A stenotic mitral valve exhibits a gauge of cusps, 
which is associated with brief and hypertrophic papillary muscles and chordae (Bharati and 
Lev 1984). In case atresia or stenosis of the mitral valve is featured, the pulmonary venous 
return is determined to pass a patent foramen ovale or a true ASD to connect with the cardiac 
main output. To refer to several authors, an intact atrial septum occurs up to 10% of patients 
with HLHS (Mahowald et al. 1982; Weinberg et al. 1986). It is associated with early exitus, 
in case it is not treated or rare anomalous morphological variations (such as a levoatrial 
cardinal vein) circumvent it (Daebritz et al. 2000; Hellmund et al. 2017). An association of 
coarctation with HLHS occured in 75% of all specimens (von Rueden et al. 1975). Several 
pathologists have affirmed the occurrence of ventricular septal defects (VSD) in around 0.9-
14% (Kanjuh et al. 1965; Mahowald et al. 1982; Bharati and Lev 1984; Aiello et al. 1990). 
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1.1.6 Genetical background  
Heritability plays a crucial, but not exclusive, role in the etiology of HLHS (Hinton et al. 
2007; Feinstein et al. 2012). Its pathogenesis underlies a multifactorial genetical basis that 
encompasses aberrant molecular processes and its correlating expression of phenotypes (Mu 
et al. 2005; Hinton et al. 2007). A causative single-gene mutation was not identified, which is 
consistent with the generally supposed scheme of polygenetic causation in many types of 
CHD. Boughman and colleagues stated a recurrence risk for HLHS of 13.5% in siblings 
(Boughman et al. 1987). According to Hinton and colleagues, first-degree kinsmen exhibit a 
recurrence risk of 18% for any cardiovascular malformation (Hinton et al. 2007). The 
pathological finding of a bicuspid AV, which depicts a representative left-sided heart 
affection, has been most frequently reported in families of HLHS patients. This indicates a 
genetical relation between the occurrence of these two entities, which was further evidenced 
by subset-linkage analyses of Hinton and colleagues (Brenner et al. 1989; Loffredo et al. 2004; 
Hinton et al. 2007). They reported a recurrence risk for first-degree relatives of 3.5% for 
HLHS (Hinton et al. 2007). HLHS is considered as genetically heterogenous (Hinton et al. 
2009). The occurrence of HLHS was found to be linked with several chromosomal disorders 
in about 10% of all affected patients (Natowicz et al. 1988; Grossfeld et al. 2004), which 
differs from an incidence of 4.2% reported by Pradat and colleagues, who reviewed three 
large registries of congenital malformations (Pradat et al. 2003). Most frequently, HLHS was 
found to be linked with trisomy 21, Turner syndrome, trisomy 18, Jacobsen syndrome and 
trisomy 13 (Natowicz and Kelley 1987; Jacobs et al. 1998; Tennstedt et al. 1999; Allen et al. 
2005; Feinstein et al. 2012). Less prevalently, HLHS is associated with the Rubinstein-Taybi 
syndrome, Smith-Lemli-Opitz syndrome, Holt-Oram syndrome, Apert syndrome, Noonan 
syndrome and a diversity of chromosomal deletions and translocations (Natowicz et al. 1988; 
Morris et al. 1990; Consevage et al. 1996; Jacobs et al. 1998; Allen et al. 2005; Feinstein et al. 
2012). A connection to the VACTERL association (acronym for vertebral anomalies, 
anorectal malformations, cardiovascular anomalies, tracheoesophageal fistula, esophageal 
atresia, renal and/or radial anomalies, limb defects) was further implied. Furthermore, HLHS 
was found to be associated with several mutations of genes, such as the cardiac homeobox 
gene Nkx-2.5, which is known to cause ASD and tetralogy of Fallot (Elliott 2004; 
McElhinney et al. 2009; Stallmeyer et al. 2010). The connexin-43-gap-junction gene and 
NOTCH-1, which plays a crucial role in physiological EndMT, are further important 
(Dasgupta et al. 2001; Risebro and Riley 2006; Iascone et al. 2012). To underline the notion 
of genetic heterogeneity, a linkage between HLHS to chromosomal loci, such as 6q23 and 
10q22, was indicated (Hinton et al. 2009). Unpublished data from the Iascone laboratory 
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found the gene KIAA0182 to be de novo mutated in a child that suffered from HLHS, which 
caused a T-C-missense mutation in exon 9 of the isoform GSE-1-202. Also unpublished data 
from Hitz and colleagues showed the occurrence of a cardiac phenotype in zebrafish with a 
KIAA0182 knockout, which was marked by ventricular size reduction and atrial enlargement. 
This implies a crucial role of KIAA0182 in cardiogenesis1. Moreover, HLHS is frequently 
associated with EFE, which is caused by aberrantly occurring EndMT (Xu et al. 2015). Many 
signaling pathways have been shown to be involved in EndMT, such as NOTCH signaling, 
the vascular endothelial growth-factor (VEGF) and TIE-2 (Lin et al. 2012). Interestingly, 
KIAA0182 was detected to participate in the complex of the RE1-silencing transcription-
factor corepressor (COREST), which was also found to be implied in epithelial-to-
mesenchymal transition (EMT), while EndMT depicts one specific form of it (Yokoyama et 
al. 2008; Lin et al. 2010; Yang et al. 2011; Lin et al. 2012). Therefore, it appears reasonable 
that KIAA0182 is involved in aberrant molecular processes of the pathogenesis of HLHS.  
 KIAA0182 depicts a human gene, which features 23 exons, 217 orthologues and 
16 transcripts (splicing variants). Among them, eight are protein-encoding with different 
isoforms of largely uncharted functions. The biggest isoform consists of 1217 amino acids 
(ncbi.nlm.nih.gov). In the year 1996, the Japanese research group of Nagase and colleagues 
published data that determined the coding sequences of 40 new genes, which were named 
KIAA0161 to 0200, among them was the gene KIAA0182 that offers alternating arginine 
and glutamate motifs (Nagase et al. 1996). To regard the orthologues of KIAA0182, the 
similarity to mouse accounts for 84.19% and to zebrafish for 60.63% (genecards.org). By 
offering 16 exons, the second transcript is the largest one with a size of 7495 base pairs (bp). 
The major difference between the frist and third transcript is missing of the second exon.  A 
leucine-zipper motif was stated to be C-terminal, where the respective protein-encoding gene 
KIAA0182 was declared to have the cytogenetic location 16q24.1 (ensembl.org/Homo_ 
sapiens; Chai et al. 2016). The gene Gse-1 (genetic suppressor element 1), the orthologue to 
KIAA0182 in mice, is located on the chromosome 8. It features seven transcripts and is 
associated with eight phenotypes, which are characterized by abnormal bone mineralization 
with a decreased bone-mineral density and a decrease of body weight and erythrocyte-cell 
number. Furthermore, increased circulating levels of alkaline phosphatase and total protein 
are phenotypically described (ensembl.org/Mus_musculus/Gene/Phenotype). Four out of 
seven splicing variants are protein-encoding (Gse-1-201, Gse-1-202, Gse-1-203 and Gse-1-
206), where isoform Gse-1-201 depicts the largest one (ensembl.org/Mus_musculus/Gene 
 
1 The author of this doctoral thesis owes these notions (of the aforementioned unpublished data) to verbal 
remarks of Ms. Prof. Dr. med. E.M. Zeisberg, received in May, 2019 
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/TranscriptComparison). To consider integrated proteomics, Gse-1 is expressed in 
monocytes, CD-8 T-cells, natural-killer cells and adult tissue of retina, pancreas, placenta, 
cervix and testis. To regard fetal tissue, Gse-1 is known to be expressed in heart, liver, ovary 
and testis (genecards.org). In the year 2016, Chai and colleagues published data of 
immunohistochemical analyses, which implied Gse-1 to function as an oncogene in breast 
cancer. Suppressing Gse-1 resulted in a significant reduction of cancer-cell proliferation, 
migration and invasion. Furthermore, Gse-1 was recognized as a target of miR-489-5p, which 
was proven to be diminished in breast cancer cells (Chai et al. 2016). A case report, which 
included Gse-1, was published in the year 2013 that found a small de novo duplication 
(16p24.1) in one patient with a striking clinical phenotype with spastic paraplegia, severe 
epilepsy, mental retardation, arachnodactyly, malar hypoplasia and an arched palate 
(Quéméner-Redon et al. 2013). In the year 2012, data were published that emphazised the 
association between the risk of colorectal cancer and variant alleles of KIAA0182, which are 
part of a single-nucleotide polymorphisms within 3’-untranslated genetic areas (Landi et al. 
2012). In the year 2008, Yokoyama and colleagues published data, which identified the 
histone-lysine-specific demethylase LSD1 as an interacting candidate of the orphan receptor 
NR2E1, also known as TLX. LSD1 mediates its transrepressive function in retinoblastoma 
cells. Among other interactants of TLX was the proline-rich protein KIAA0182 of uncharted 
function (Yokoyama et al. 2008). Hakimi and colleagues have shown five years in advance, 
that LSD1 interacts with KIAA0182 (Hakimi et al. 2003). Furthermore, LSD1 is part of many 
protein complexes, such as COREST (Yang et al. 2011). The tenary complex of LSD1, 
COREST and SNAIL1 is implied in EMT, where the process of EndMT depicts one form 
of it. In EMT, SNAIL1 was identified as a key-regulatory protein. COREST was shown to 
function as an enhancer of the stability of the tenary complex (Lin et al. 2010). Gse-1 is 
involved in the formation of circular RNA (circRNA), whose function is largely unknown 
(Memczak et al. 2013). Memczak and colleagues published data that allocate the function of 
post-transcriptional regulators to circRNA, which exhibits a “mi[cro]RNA-binding capacity” 
that is “ten times higher than [in] any other known transcript” (Memczak et al. 2013).  
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1.2 Cardiac development 
1.2.1 Human cardiogenesis 
Human cardiogenesis starts at the third week of development (estimated gestational age 
[EGA]) with a process known as gastrulation (Moorman et al. 2003), where the germ layers 
obtain their embryonic position. They consist of the ectoderm, the endoderm and the 
mesoderm. The last-mentioned contributes to the formation of the so-called cardiac crescent 
that simultaneously arises to the neural plate, which consists of ectoderm (Moorman et al. 
2003). Different cell types populate the cardiac crescent, among others, promyocardial cells 
and endothelial strands. They contribute to the morphogenesis of the heart tube that is 
partially composed of an endocardial tube, which in turn enables the communication of the 
growing heart with a circulatory system (Moorman et al. 2003). Within the newly formed 
pericardial cavity, the endocardial tube is coated by myocardial cells. Looping of the heart 
tube represents the next procedural step, whose initiation is a requirement for chamber 
morphogenesis. It is the first asymmetric event during cardiogenesis, which occurs at around 
four weeks EGA (Moorman et al. 2003). The event of chamber formation is composed of 
simultaneously occurring ventricular and atrial morphogenesis, where the last-mentioned 
depends on the formation of the lungs. The pulmonary veins, which emanate form the 
pulmonary vascular plexus that surrounds the lung buds, connect with the heart tube’s 
primary atrial component (Moorman et al. 2003). The formation of the ventricles advances 
by curvature ballooning of the heart loops apical part, where the atrio-ventricluar canal walls 
join the LV (Moorman et al. 2003). From day 48 until day 66 EGA, EndMT promotes 
valvular morphogenesis. The refinement of the semilunar and atrioventricular valves (AVV) 
occurs from day 56 EGA onwards (Krishnan et al. 2014; Gong et al. 2017). EndMT is known 
to contribute to crucial cardiogenetic events, such as the formation of the valves and the 
septum, but also pathogenetical processes like cardiac fibrosis (Person et al. 2005; Krenning 
et al. 2010). The process of septation, where the atrioventricular and ventricular septum is 
formed, occurs from eight until nine weeks EGA in human cardiogenesis (Krishnan et al. 
2014).  
1.2.2 Cardiogenesis in mice 
The transferibility of cardiogenesis in mice to humans legitimates animal research in mice. 
Simplifyingly, mammalian cardiogenesis can be itemized into a multi-step process. Fate 
determinition of cardiomyocytes and their further specification, morphogenesis of the 
cardiac tube, formation of the heart loop, chamber maturation, morphogenesis of the vavular 
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structures from endocardial cushion tissue (ECT) by EndMT, the process of atrial and 
ventricular septation, myocardial compaction and valvular refinement will be explicated 
(Bartman and Hove 2005; Zhang et al. 2013; Krishnan et al. 2014). Among others, the 
descriptive attention will be drawn to a few selected cardiogenetic events, such as chamber 
maturation with the processes of trabeculation and compaction. Figure 1 gives a simplified 
overview of the major cardiogenetic events, which are explicated in the continuous text.  
 
1.2.2.1 The primary and secondary heart field and the heart-tube formation 
At an early developmental age in mice around E7 post conceptionem (p.c.), the heart begins to 
develop. An embryonic structure called primitive streak is populated by cardiac precursor 
cells of the primary heart field, which forms the cardiac crescent at E7.5 p.c. (Risebro and 
Riley 2006). Dorsally and medially to it, the second lineage is localized, which depicts a 
cardiogenic area from an additional population of pharyngeal mesoderm cells (Kelly and 
Buckingham 2002; Risebro and Riley 2006; Dyer and Kirby 2009). At around E8 p.c., the 
invading endoderm induces the tubular heart formation in the anterior lateral mesoderm by 
migration and fusion of progenitors of the primary heart field at the ventral midline of the 
embryo. Extracellular matrix (cardiac jelly) represents the formating basis for the 
juxtaposition of single-cell laminas of myocardium and endocardium (Bartman and Hove 
2005; Risebro and Riley 2006; Zhang et al. 2013). The linear heart tube, which is connected 
to the thoracic wall by the dorsal mesocardium, is the originator of contractive waves (de 
Jong et al. 1992; Lamers and Moorman 2002; Risebro and Riley 2006). Retrospective clonal 
analysis is a biochemical method based on spontaneous mitotic recombination that utilizes 
an inactivated lac-Z-reporter gene. By means of it, it was revealed that the colonization of 
progenitor cells from both the primary and secondary heart field equally contribute to the 
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formation of the heart tube. In contrast to that, the outflow tract, which originates from the 
second lineage and the LV, obtains its cellular sources from the primary lineage (Meilhac et 
al. 2004; Risebro and Riley 2006). Conflictingly to these findings, genetic fate-mapping 
studies have implied that the cellular sources of the LV are not exclusively restricted to the 
primary lineage, but also originate from the secondary lineage (Verzi et al. 2005).   
1.2.2.2 Cardiac looping 
At embryonic age E8.25 p.c. until E10.5 p.c., rightward looping represents the next 
procedural step during cardiogenesis. Synchronically, the second cardiac lineage has a share 
in the formation of the venous and arterial pole of the heart by precursor migration of the 
second lineage (Risebro and Riley 2006). The fact that it occurs in every species of the 
vertebrates underlines the outstanding decisiveness of this event (Risebro and Riley 2006). 
Cardiac looping enables vascular positioning and ventricle formation. At the ending of this 
process, the atrioventricular canal forms the prospective LV. It is connected to the outflow 
area that will evolve into the great cardiac vessels and the inflow region, which is interlinked 
with the atria (Risebro and Riley 2006). CHD such as VSD or double outlet RV (DORV) 
can be attributed to aberrancies during cardiac looping with an ineligible outflow-tract 
formation or an incorrect connection of the vessel level and the ventricular septum (Risebro 
and Riley 2006). Several researchers have contributed to the revelation of molecular 
keyplayers in the event of cardiac looping with mouse models for loss of function (LOF). 
During the complex process of cardiac looping, several genes play decisive roles. Important 
representatives are the myocyte-specific enhancer factor 2C (Mef2c), the fibroblast growth 
factor (Fgf), the heart and neural crest derivatives-expressed protein 1 (Hand1), the gene 
Nkx-2.5 and the forkhead box protein H1 (FoxH1; Lyons et al. 1995; Lin et al. 1997; Linask 
et al. 2002; Dodou et al. 2004; von Both et al. 2004; Verzi et al. 2005).  
1.2.2.3 Septation and valvulogenesis 
The process of septation enables the formation of a definite two-sided heart. The processes 
of atrial, atrioventricular and ventricular septum formation can be distinguished by their own 
cellular characteristics (Anderson et al. 2003). Occuring between E10.5 p.c. and E14.5 p.c. 
in the mouse embryo, septation promotes the cardiac function of unidirectional blood 
circulation (Risebro and Riley 2006). Synchronically to cardiac looping and chamber 
morphogenesis, the formation of the interventricular septum (IVS) starts in the heart tube 
(Lamers and Moorman 2002). The abovementioned processes of EndMT and EMT are 
considered to play major roles by enabling cell transformation with the groundwork of ECT 
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to promote morphogenesis of membranous septa and valves (Kinsella and Fitzharris 1980; 
Eisenberg and Markwald 1995; Person et al. 2005; Risebro and Riley 2006; Zhang et al. 2008; 
Lin et al. 2012). Valve precursors colonize ECT, where the last-mentioned are progressed 
into valve formation by EndMT (Person et al. 2005). EndMT was further shown to play an 
important role in embryogenetic and neoplastic events, such as tumor progression and 
malignant transformation (Lin et al. 2012). 
1.2.2.4 Chamber formation 
The morphogenesis of chambers is promoted by formation of the bulbus cordis (BC). To cope 
with the increment in volume load, which enables oxygen and alimentary supply in the 
developing embryo, chamber maturation progresses by advancing ventricular septation, 
trabeculation and compaction (Risebro and Riley 2006). Extensive studies have been 
performed to examine the expression patterns of certain transcrpition factors, which proved 
to be chamber-specific. For instance, Hand1 is specifically expressed in the LV, where Hand2 
prevailingly shows expression patterns in the RV (Srivastava et al. 1997). Christoffels and 
colleagues proposed a two-step model for chamber formation, which challenged and even 
rejected the predominant conception of a linear heart tube as an array of segments (Stalsberg 
1969; Anderson et al. 1978; de la Cruz et al. 1989). Christoffels and colleagues performed in-
situ hybridization with rat embryos to study gene expression in the developing heart, which 
led to the revision of the former conception and to common acceptance of the two-stepped 
ballooning model (Risebro and Riley 2006). The first step deals with the generation of a 
primary transcriptional signature, which is associated with the linear heart tube and the 
cardiac crescent. It is polarized along the anteroposterior and dorsoventral axes. The second 
step embraces the establishment of the secondary transcriptional program that is linked to 
the chambers of the heart (Christoffels et al. 2000). The primary transcriptional pattern is 
executed in the inflow and outflow tract, the atrioventricular canal and the inner curvature 
of the developing heart. The second transcriptional program is found to be active in the 
outer curvature of the looping heart that enables the chamber myocardium to balloon out. 
Expressed genes, such as the atrial natriuretic factor, Chisel, iroquois homeobox 5 (Irx5) and 
upregulated transcription factors like the sarcoplasmic reticulum-calcium ATPase 2a, Mlc2v 
and Irx4, were analyzed by in-situ hybridization that led to the assumption of side-specific 
morphogenesis of the chamber myocardium (Christoffels et al. 2000). This notion is further 
supported by regional differences in clonal growth found by other researchers. The LV finds 
its mophology by bulging out of the outer curvature, where the RV is shape-defined by 
tubular enlargement (Meilhac et al. 2004; Risebro and Riley 2006).    
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1.2.2.5 Ventricular trabeculation and compaction 
At early midgestational age, the invagination of endocardial cells in addition to 
cardiomyocytes, which protrude into the lumen, facilitates accretive myocardial 
trabeculation. The exterior layers of cardiomyocytes give rise to progressive myocardial 
compaction (Zhang et al. 2013). The decisive role of endothelial induction of this process is 
widely accepted (Stainier et al. 1995; Liao et al. 1997). Extensive studies have been performed, 
which imply the importance of reciprocal interaction between the endo- and myocardium. 
To name representative signaling molecules, neuregulin, serotonin 2B and angiopoietin 1 
proved to be important for the communication between the endo- and myocardium 
(Gassmann et al. 1995; Lee et al. 1995; Meyer and Birchmeier 1995; Sato et al. 1995; Suri et 
al. 1996; Miquerol et al. 1999; Puri et al. 1999; Nebigil et al. 2000). Trabecular expansion 
occurs via myocytical proliferating or recruiting, where trabeculation was suggested to be a 
means to cope with the increasing force demand of a growing heart. It enables oxygen and 
alimentary supply from E9.5 p.c. until around E14.5 p.c. (Sedmera et al. 2002; Risebro and 
Riley 2006; Zhang et al. 2013; Captur et al. 2016). By E14.5 p.c., myocardial compaction is 
completed (Sedmera et al. 2002; Risebro and Riley 2006; Zhang et al. 2013). Moreover, the 
occurrence of trabeculated myocardium is associated with a progressive replacement of 
cardiac jelly (Blausen et al. 1990). The regulation of cardiac jelly plays an important role in 
atrial chamber morphogenesis, which remains poorly understood compared to ventricular 
chamber formation (Kim et al. 2018).  
Signaling of bone-morphogenic protein 10 (Bmp-10), which is important for atria 
formation after E13.5 p.c., was proven to be crucial for trabeculation between E9.0 p.c. and 
E13.5 p.c., where Bmp-10-deficient mice die around E10.5 p.c. because of insufficient 
trabecular growth (Chen et al. 2004). Mammalian hearts expose a morphological difference 
between right- and left-ventricular trabeculae (Risebro and Riley 2006). Among vertebrate 
species, differences in the trabecular morphology are statable with regard of human, rodents, 
avian and fish hearts, where humans expose right- and left-ventricular distinction concerning 
the myocardial width (Webb et al. 1996). Apical and basal disparities are observable in 
mammals and birds, in contrast to fish hearts that do not regionally differ in terms of an 
apical-to-basal axis (Hu et al. 2000). The process of trabeculation advances at a late 
midgestational age, where the major part of trabeculated myocardium becomes compacted 
by solidifying towards the ventricular wall. Thereby, it progressively takes over the function 
of contractile force supply (Sedmera and Thomas 1996; Hu et al. 2000; Zhang et al. 2013).   
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Induction of myocardial compaction is observable around E11.5 p.c., where a 
significant increase in ventricular compaction width with augmenting structural complexity 
is detectable at E13 p.c. to E14 p.c. (Wessels and Sedmera 2003; Risebro and Riley 2006). 
Several molecular keyplayers have been found to play a decisive role in the complex event of 
myocardial compaction. In the year 1993, two independent research groups from Japan and 
Canada demonstrated the importance of the transcription factor N-myc for the development 
of compacted myocardium (Moens et al. 1993; Sawai et al. 1993). N-myc is crucial for an 
advanced development of compacted ventricular layers in terms of expansion and 
interventricular septation, since N-myc-deficient mice expose severe defects in those 
categories and die around E10.5 p.c. (Moens et al. 1993; Sawai et al. 1993). Kokoszka and 
colleagues characterized ventricular non-compaction as “the persistence of multiple prominent 
ventricular trabeculations and deep inter-trabecular recesses“ (Kokoszka et al. 2016). The 
complications that occur due to non-compaction in adult and in embryonic hearts are 
diverging. In adult humans, non-compaction exhibits a relatively broad pathological 
spectrum. It ranges from sudden cardiac death to a mild form of left-ventricular non-
compaction that is typically marked by a triad of cardiac arrhythmias, the appearance of mural 
thrombi and heart failure. Often, it remains underdiagnosed (Waller et al. 1980; Wessels and 
Sedmera 2003; Jenni et al. 2007; Luxán et al. 2016; Choquet et al. 2018; Huang et al. 2018). 
In a review, Risebro and Riley stated that mice, which exhibit defects in myocardial 
compaction, usually die around E14 p.c. from congestive heart failure. This underlines the 
crucial function of effectual compaction during cardiogenesis (Risebro and Riley 2006). 
Sedmera and colleagues studied cellular changes, which occur because of left-atrial ligation 
in an embryonic HLHS-chick model (Sedmera et al. 2002). Embryonic cardiomyocytes are 
capable of proliferation-rate autoregulation, which adapts to mechanical requirements. It 
depicts the cellular basis for responsiveness to functional loading of the heart (Sedmera et al. 
2002; Risebro and Riley 2006). Communicative signaling between compacted and 
trabeculated myocardium is another important process contributing to adequate chamber 
maturation in terms of trabeculation and compact-zone formation (Risebro and Riley 2006). 
In the HLHS-chick model, the interaction between mechanical loading and expanding of the 
LV is disturbed. This results in a hypoplastic LV with a striking reduction of ventricular 
volume (Sedmera et al. 2002; Risebro and Riley 2006). However, the transferability of the 
findings in chick embryos to human remains to be elucidated.  
Synchronically to the process of compaction, the heart develops with respect to 
coronary vasculogenesis and interventricular septation, where the coronary development 
underlies a gradient from epi- to endocardium and from basis to apex (Pignatelli et al. 2003; 
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Risebro and Riley 2006). Regarding transmembrane type semaphorin 6D, which interacts 
with plexin A1, avian heart studies provided insights to the regulation of myocardial cell 
motility in analogy to its function in axonal guidance (Bashaw et al. 2000; Toyofuku et al. 
2004). Many LOF-mouse models that presented the non-autonomous cell function of several 
genes have underlined the importance of the intricate interplay between myo- and 
epicardium. Mutant mice for Wilm’s tumor gene 1 (Wt-1) are characterized by a thinned 
ventricular compact zone (vCZ) implying a non-autonomous cell function in contrast to the 
aforementioned N-myc, which participates in Notch signaling (Kreidberg et al. 1993; Moens 
et al. 1993; Sawai et al. 1993; Luxán et al. 2016). Among others, Wt-1 shows epicardial 
expression patterns (Kreidberg et al. 1993). 
1.3 Mutagenesis strategies and Gse-1 mice 
In the year 2003, the human genome project was declared completed after having unravelled 
the base sequence of the human genome, which enabled identifying about 20000 to 25000 
genes in the human deoxyribonucleic acid (DNA; genome.gov). Deciphering the DNA 
sequence depicted a major step towards the elucidation of the biological functionality of the 
mammalian genome. But taken for itself, it is insufficient to explain cellular functionality of 
single genes. Facing a multidimensional complexity of intracellular molecule interactions has 
led to the development of diverse approaches to generate clear correlations between a gene 
and its biological function. Monogenetical diseases, such as sickle-cell anemia or cystic 
fibrosis, provided the principle of correlation between a single-gene mutation and its 
respective phenotype, where few diseases exhibit a monogenetical causation. It has been 
aspired by researchers to transfer this principle to animal models, which enable the inclusion 
of single-gene mutations in biological organisms. Biomolecular techniques, such as 
mutagenesis, allow a relatively targeted distraction of a cellular system on the level of genetic 
transcription. The possibility to produce mutations (by circumscribed controllable methods) 
represents a powerful implement of understanding the pathogenesis and evolution of many 
human diseases.  
1.3.1 Gene trapping 
The advent of gene trapping represents the transition between randomly and precisely 
defined mutations (Stanford et al. 2001). The introduction of a trapping vector can either be 
performed by retro-viral transfection or by electroporation, which is mostly leading to 
random genomic integration (Li and Zhang 2006). This method found its modification in 
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the species drosophila melanogaster and the mouse (Stanford et al. 2001). Three types of vectors 
presented the basis for gene trapping (gene-trap, enhancer and promoter vectors), where 
each one exhibits a profile of features, which originally was used for mutagenesis of 
embryonic stem (ES) cells (Stanford et al. 2001). Enhancer-trap vectors function to trap 
diverse loci by being juxtaposed to a cis-acting enhancer element, which favors expression 
of the lac-Z-reporting gene (Gossler et al. 1989). Seldomly, this method was found to be 
associated with LOF mutations in mice, which are highly requested. Promoter-trap vectors 
usually are constructed of a reporting gene, which is promoterless. It enables the function of 
selection in case of successful insertion (Stanford et al. 2001). Exonic insertions are 
commonly acquired with promoter-trap vectors because of their molecular construction. 
Therefore, promoter-trap vectors seldomly expose hypomorphic mutations, but show a 
lower frequency of vector insertion than enhancer traps (Stanford et al. 2001). Gene-trap 
vectors are characterized by fusion-transcript generation, which consists of the reporter gene 
and the upstream-coding sequence that enables the coincidental mutation of a gene. Since 
the occurrence of intron insertions lies at hand, one great detriment is the sporadic occurence 
of hypomorphic alleles (Stanford et al. 2001).  
1.3.2 Knockout-first allele of Gse-1 mice and previous results 
Depicting a modification of gene-trap vectors, the knockout-first allele, referred to as 
targeted mutation 1a (Tm-1a), was designed to provide a Gse-1 knockout on transcription 
level from the beginning on without further breedings (compare figure 2). Our research 
group acquired a mouse model based on the knockout-first Tm-1a allele with ES cells 
provided by the European conditional mouse mutagenesis program (EUCOMM). It 
systematically aims to provide ES cells of mutant mice on black-6N-genetic background for 
further research purposes to generate a library of protein-encoding genes and their 
correlating function. The EUCOMM is a member of the international knockout mouse 
consortium (IKMC), which consists of four great members and features the former 
mentioned core principles of the EUCOMM (mousephenotype.org). Being translated from 
the largest isoform Gse-1-002, the generated protein is supposed to be truncated, including 
the first 85 amino acids of the wild-type (WT) protein. The Tm-1a allele contains a triad of 
casettes with an engrailed 2 splicing acceptor (En2 SA), an internal ribosomal entry side 
(IRES) and a polyadenylation (poly-A) signal for termination of the transcription. It allows 
reporting of gene expression synchronically to terminating gene transcription of the targeted 
Gse-1 gene. The lac-Z casette encodes for the enzyme β-galactosidase, which enables a gene 
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reporting function. The third exon of the isoform Gse-1-002 is flanked by two surrounding 
LoxP sites, which stands for locus of cross-over P. Therefore, the third exon is floxed 
(flanked by LoxP). After the En2SA/IRES/lac-Z casettes, a floxed triad of casettes follows, 
which consists of a promoter driven casette for the human β-actin autologous promoter 
(hBactP), a neomycin-resistance cassette, which is further followed by a poly-A-termination 
signal. The first and second triad of casettes is flanked by sites for the flippase-recognition 
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target (FRT) that enable rearrangement by the flippase (Flp) recombinase (Skarnes et al. 
2011). When breeding Tm-1a mice to Flp-expressing mice, a conditional allele can be 
obtained, which is referred to as Tm-1c. It restores gene activity. This further can be 
converted into a null allele with an excision of the third exon that generates a frameshift 
mutation (Tm-1d) by breeding Tm-1c mice with mice that express a cyclisation recombinase 
(Cre). When breeding Tm-1a embryos directly to Cre-expressing mice, a lac-Z-tagged null 
allele can be achieved, which is called Tm-1b (compare figure 2; Skarnes et al. 2011; Ryder 
et al. 2014).  
 In a previously performed study by Alnour, heterozygous Gse-1 mice were mated and 
genotyping of their pubs was performed based on two protocols. Quality controls to affirm 
correct targeting of Gse-1 were performed by long-range and short-range polymerase chain 
reaction (PCR). Genotyping results of 134 newborn mice by three weeks of age from 23 
litters showed that no homozygous mice were maintained, which strongly indicated 
embryonic lethality of Tm-1a homozygosity. With an expected Mendelian ratio of 1:2:1, the 
chi-square test offered a p-value of less than 0.0001 and a g-power of 99.999%. Genotyping 
of newborn mice from mating WT and heterozygous mice showed no significant deviation 
from the Mendelian ratio of 1:1 with a p-value of 0.125, which implied no lethal effect of 
Tm-1a heterozygosity (Alnour 2016).   
1.4 Objective of  this study 
As described above, the overall aim of this study is to elucidate molecular mechanisms of 
HLHS. Based on a) the documented de novo mutation of KIAA00182 (analogue to Gse-1 in 
mice) in a child with HLHS and b) the documented lethality of homozygous Gse-1 mice by 
three weeks of age, the objectives were the following: 
1. identify the timepoint of lethality in homozygous Gse-1 mice 
2. analyze if a cardiac phenotype is present in homozygous Gse-1 mice 
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2.1 Experimental procedures 
2.1.1 Generation of Tm-1a mice 
Mice were generated from ES cells provided by the EUCOMM, where the number of the 
project is 71610 and the number of the cell clone is EPD0557-2-C07 (knockoutmouse.org). 
All mice were maintained on black-6-N background. The allele (Gse-1tm-1a(EUCOMM)Wtsi) has the 
previously described knockout-first design (compare figure 2). It was inserted in the gene 
region of Gse-1 by homologous recombination. This construct is designed to disrupt gene 
function on the transcriptional level. The provider has performed quality-control tests, 
including southern blotting, karyotyping, LoxP-sites confirmation, 3’- and 5’-end long-range 
PCR (knockoutmouse.org). The local animal-experimental committee of the University 
medical center of Göttingen (UMG) approved all animal experiments that were performed. 
The usage of all animals was conducted in accordance with the institutional guidelines. 
Furthermore, the mice received humane care (food and water supply ad libitum) and housing 
under standard conditions in the animal facility of the UMG.  
2.1.2 Timed matings 
To investigate potential developmental defects that lead to embryonic lethality, homozygous 
Tm1-a embryos were generated by mating heterozygous Tm1-a mice. Timed matings were 
arranged for the developmental days E11.5 p.c., E13.5 p.c. and E15.5 p.c. The appearance 
of a vaginal plug was designated as embryonic day E0.5 p.c. The pregnant mouse was fed 
with food and water based on the institutional guidelines for humane animal care. The weight 
of the mouse was gauged daily.  
2.1.3 Dissection of embryos and labeling with identity number  
Harvesting of embryos at the developmental timepoints E11.5 p.c., E13.5 p.c. and E15.5 p.c. 
was performed. Therefore, pregnant mice were anesthetized with isoflurane and laired on 
their abdomen. The mice were put to death by cervical dislocation in a dignified manner. 
After having turned them backwards, the abdominal cavity was disclosed by cutting open the 
abdominal wall. Both uterine horns were dissected in an attentive way.  They were put into 
Dulbecco’s phosphate-buffered saline. Embryos were separated from the layers of the 
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uterus, placenta, amnion and yolk sac. The number of the somites confirmed the embryonic 
age for early ages (E9.5 p.c. to E11.5 p.c.).  Each embryo was labeled with an individual 
number of identity (in the following referred to as embryo ID) by the following scheme of 
y.x, where y depicts the three-figured number of identity of the maternal mouse and x is the 
ID number of the embryo. The y number indicates the fact that embryos are from the same 
litter. The succession of the labeling represents the order of embryonic dissection.  
2.1.4 Morphological examination 
Tissue samples, mostly the left-sided limbs, were extracted. Tm-1a embryos were 
photodocumented from both sides with a microscope (Zeiss SteREO Lumar. V12) and the 
respective program (Axio Vision Rel 4.8). The remnant embryo was fixated in 4%-
paraformaldehyde (PFA). Tissue extractions were deep-frozen in liquid nitrogen. They were 
further utilized for the extraction of DNA.  
2.1.5 Genotyping  
2.1.5.1 Extraction of desoxyribonucleic acid 
2.1.5.1.1 From freshly frozen tissue 
Using the standard manufacturer’s protocol, DNA extractions from freshly frozen tissue 
were performed with a commercial kit (DNeasy Blood & Tissue) by Qiagen. Tissue samples 
were incubated for 12 hours at 56 °C in a solution that contained lysis buffer and proteinase 
K (a serine protease from the fungus engyodontium album), which led to cell lysis and DNA 
liberation. Subsequently, an ethanol precipitation was carried out. Several steps of 
centrifugation were performed to further purify the genomic DNA. To finish DNA 
extraction, a buffer was added to elute the DNA into a microcentrifuge tube. Subsequent 
measurements of the concentration were performed. The genomic DNA was stored at 4 °C.  
2.1.5.1.2 From formalin-fixed, paraffin-embedded tissue 
Using the standard manufacturer’s protocol, DNA extractions from formalin-fixed, paraffin-
embedded (FFPE) tissue were performed with a kit (QIAamp DNA FFPE Tissue) by Qiagen. 
Eight sections of an embryo-containing paraffin block were produced with the respective 
thickness of 5-8 μm. The first step is depicted by deparaffinization of the FFPE tissue with 
xylene. After having lysed the cells with a solution that contains lysis buffer and proteinase 
K, the samples were incubated at 90 °C to foster the cancellation of formalin crosslinks. To 
eradicate the contaminating components of the lysate, the DNA binded to a positively 
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charged membrane, where the contaminants seeped through the pores of the membrane. In 
several washing steps, the DNA was purified. To complete the extraction, the DNA was 
eluted with a buffer. After having subsequently measured the concentration, the DNA-
containing solution was stored at 4 °C. 
2.1.5.2 Polymerase chain reaction  
To perform PCR, a solution was generated that had a reaction volume of 25 μl. It contained 
0.3 μl taq-polymerase, 2.5 μl of a taq-polymerase-compatible buffer (ten-fold), 2.5 μl of a 
magnesium-chloride solution (25 mM), 1 μl of a desoxynucleotide-containing solution (2 
mM), 50-100 ng of the genomic DNA, 20 μM of each primer, 0.5 μl of dimethyl sulfoxide 
and the differential volume of nuclease-free water. All PCRs were performed with 35 cycles. 
One cycle was arranged as follows: phase 1: 95ºC for ten min., phase 2: 95ºC for 15 sec., 
60ºC for 30 sec., phase 3: 72ºC for 30 sec., 72ºC for eight min. Phase 2 was repeated 32 
times, one cycle was finished with a holding temperature of 8ºC. The primer’s sequence will 
be enlisted below (compare table 3). A triad of primers (Gse-1-5arm-WTF [1.], Gse-1-crit-
WTR [2.] and Tm1a-5mut-R1 [3.]) was utilized for genotyping Tm-1a mice. Two PCR 
products were achieved. The first amplicon (WT band) with a size of 241 bp was obtained 
with the pair of primers WT forward (Gse-1-5arm-WTF [1.]) and WT reverse (Gse-1-crit-
WTR [2.]). Gse-1-5arm-WTF (1.) anneals to the 5’-homology arm and Gse-1-crit-WTR (2.) 
anneals to the 3’-homology arm (compare figure 2). Because of the design of the Tm-1a 
allele, no PCR product is achieved in homozygous specimens, because the amplicon would 
be too big to be obtained under the former mentioned reaction conditions. Therefore, 
homozygous specimens show no WT band of 241 bp. The second amplicon offers a size of 
127 bp, which is obtained with the primer pair of the universal mutant primer (Tm-1a-5mut-
R1 [3.]) and the WT forward primer (Gse-1-5arm-WTF [1.]), where the third primer is set at 
the location before the first FRT site (compare figure 2). Because of the alellic set-up, WT 
embryos offers no annealing of the primer Tm-1a-5mut-R1, therefore, WT specimens do 
not expose a mutant band of 127 bp.  
2.1.5.3 Agarose gel electrophoresis 
The sizes of the maintained PCR products for the Tm-1a allele account for 241 bp and 127 
bp. To visualize the amplified PCR product, a 3%-agarose gel was prepared. Therefore, 200 
ml of a buffer, which contains tris base, ethylenediaminetetraacetic acid and acetic acid 
(TAE), was mixed with 6 g of agarose powder. It was boiled in a microwave for five min. A 
SYBR-containing gel stain was added in an attenuation of 1:10000 and equally distributed. 
Each gel pocket was filled with a volume of 15 μl of the PCR product and 5 μl of a six-fold 
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loading dye. Furthermore, to identify the size of the amplicon two DNA ladders were 
additionally added into separate gel pockets. Finally, the gel chamber (containing the loaded 
gel and TAE buffer) was left to run for 15 min. with 80 Volt and then approximately 45 min. 
with 120 Volt. The image of the gel was documented with the special equipment for image 
acquisition (BioDocAnalyze) to identify the genotype of the embryos. WT genotype offered 
one band of 241 bp, homozygous genotype produced one band of 127 bp and heterozygous 
genotype yielded both bands.  
2.1.5.4 Statistical analysis 
The acquired genotyping results were statistically analyzed with the chi-square test. The 
Mendelian ratio of 1:2:1 (WT: heterozygous: homozygous) of heterozygous Tm-1a breedings 
constitutes the expected quantities.  P-values under 0.05 were considered to be statistically 
significant.  
2.1.6 Histological methodology 
2.1.6.1 Fixation of embryos 
The entire embryos were fixated with 4%-PFA at 4˚C for at least 24 hours. Alternatively, a 
fixation with a commercially acquired, acidfree, phosphate-buffered solution containing 4%-
formaldehyde (Roti Histofix 4%) was applied.  
2.1.6.2 Dehydration and ascending ethanol gradient 
To prepare the embryos for paraffin embedding, the fixed embryos were put under slowly 
flowing tab water for 12 hours. They were dehydrated by using an ascending ethanol gradient 
(20%, 40%, 60%, 80%, 90%, 96% and 100%). After having gone through this ascending 
ethanol gradient, each for a duration of 30 min., the embryos were treated with xylene to 
proceed to paraffin embedding. 
2.1.6.3 Embedding and orienting embryos in paraffin wax 
Before cooling down the paraffinized embryos in a block of paraffin wax, one had to 
consider the proper orientation of the embryos. Depending on the mode of sectioning, i.e., 
whether the histology should be in line with transverse or sagittal sections, the embryos were 
oriented in the paraffin block. Each embryo of the identical litter was oriented in the same 
way to guarantee the same mode of sectioning for all embryos. Long-term storage of the 
paraffin blocks was carried out at room temperature.  
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2.1.6.4 Serial sectioning 
Before producing serial sections, the paraffin blocks were cooled down at 4 °C for four hours 
to alleviate cutting. The correctly oriented paraffinized embryos were cut with a microtome. 
The thickness of each section depicted 5-8 μm.  Each sequence of pelliciles was first put on 
the surface of cool water for at least 10 min. Then, it was proceeded to 37 °C-warm water 
for at least ten min. to guarantee an equal distribution of the paraffin layer. The paraffin 
pelliciles were collected on serially numbered object slides, which were labeled with the 
respective embryo ID.  
2.1.6.5 Staining with hematoxylin and eosin 
 
Table 1 shows the entire eight-stepped process of staining with hematoxylin and eosin 
(H.E.). For H.E. staining the object slides were deparaffinized with a descending alcohol 
gradient as follows. For 20 min. the slides were kept in xylene, then for five min. in 100%-
ethanol, for five min. in 95%-ethanol and for five min. in 70%-ethanol. To continue, the 
slides were stained with hematoxylin for six min. to perform a nuclear staining. To complete 
the nuclear staining, the object slides were irrigated with floating tap water for ten min. 
Before eosin staining was conducted, the slides were shortly submerged in distilled water. To 
visualize the cellular cytoplasm, eosin staining was performed for two min. To this step 
another submerging in distillated water was affiliated. The stained sections first had to 
undergo an ascending alcohol sequence. They were kept in 96%-ethanol for one min., then 
in 100%-ethanol for four min. and finally in xylene for ten min. The staining procedure was 
finished as soon as the slides were covered with a mounting medium and glass covers.  
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2.1.6.6 Photographical acquisition 
The examination and the photographical documentation of the H.E.-stained tissue sections 
were performed with a microscope (Olympus-BX43), a camera (Olympus-SC30) and the 
respective computer program (cellSens Dimension 1.6).  
2.1.6.7 Measurement of the widths of the ventricular compact zone 
 
Homozygous embryos with respective litter-internal WT controls from the genotyping 
cohort were included. The exact inclusion of candidates will be explicated in the results part. 
The width of the vCZ was separately gauged for the RV and LV five times in each section 
level. Figure 3 shows a schematic of it. To enable a representative assessment of the entire 
ventricular myocardium, the assessed section levels were chosen to hold a minimum distance 
from each other. For E11.5 embryos, the four measured levels were chosen to be at least 10 
μm apart, for E13.5 embryos, at least 30 µm apart and for E15.5 embryos, to be at least 50 
μm apart from each other. In total, 20 measuring values were aquired per ventricle of the 
reviewed heart.  
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2.1.6.8 Statistical analysis  
The average of 20 values was calculated for each measured heart, respectively for the RV and 
the LV. For each embryonic age of E13.5 p.c. or E15.5 p.c., two cohorts were formed. A 
cohort of homozygous specimens and a cohort of WT controls. Depending on the number 
of included specimens per embryonic age, the average values of the homozygous cohort were 
compared to the average values of the control cohort by means of an unpaired two-sided, 





2 Experimental procedures and materials 35 
2.2 Materials 
2.2.1 Buffers and chemical reagents 
Table 2 presents a list of all buffers and chemical reagents, which found utilization.  
2.2.2 Primers 
The sequences of the primers, which were used for PCR, are shown in table 3.  
 
2.2.3 Commercial kits, instruments and equipment 
 
Table 4 shows all commercial kits, which were used for DNA extraction from freshly frozen 
tissue samples and FFPE tissue samples. Table 5 shows an overview of the instruments and 
the equipment, which found utilisation in this project, where the respective function is 
outlined in the last column.  
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3.1 Genotyping results 
Previous results showed that mating heterozygous Gse-1 mice delivered no homozygous 
Tm-1a pubs by the age of three weeks. Embryological lethality of Tm-1a homozygosity was 
hypothesized. Therefore, genotyping Tm-1a embryos was performed to identify the 
timepoint of embryonic lethality.  
Three developmental ages have been chosen with the distance of two days in between 
them: E11.5 p.c., E13.5 p.c. and E15.5 p.c. For each defined timepoint, terminated matings 
were arranged to respectively collect at least 30 embryos. At the first timepoint (E11.5 p.c.), 
eight litters were collected. In total, 54 embryos resulted with an average litter size of 6.8 (SD 
+/- 1.5). The second timepoint of E13.5 p.c. yielded an amount of 47 embryos from five 
litters with an average of 9.4 (SD +/- 2.1) embryos per litter. The third delopmental age of 
E15.5 resulted in a collection of 37 embryos, which originated from six litters with an average 
litter size of 6.2 (SD +/- 2.6) embryos. The sum of all collected embryos was 138, including 
one autocatalyzed E15.5 embryo with an unknown genotype.   
 
Figure 4 visualizes the genotyping results for Tm-1a homozygosity. The 
developmental age E11.5 p.c. offered an incidence of the homozygous embryos of 25.926%, 
because 14 out of 54 embryos were homozygous. The developmental stage of E13.5 p.c. 
provided a homozygous frequency of 17.021% with eight out of 47 embryos being genotyped 
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as homozygous. The embryonic age of E15.5 p.c. proved to have six homozygous from 36 
embryos (one autocatalyzed embryo with an unknown genotype was excluded), which 
resulted in an incidence of 16.216%. It is noticable that the incidences of homozygous 
embryos for the developmental ages of E13.5 p.c. and E15.5 p.c. lie under the expected 
Mendelian ratio of 25%.  
Table 6 visualizes the global genotyping results. At the embryonic day E11.5 p.c., 26 
out of 54 embryos proved to be heterozygous. The incidence is 48.148%. At developmental 
day E13.5 p.c., the incidence of Tm-1a heterozygosity amounts to 46.809%, where 22 from 
47 embryos were genotyped as heterozygous. The third timepoint E15.5 p.c. yielded a 
heterozygous incidence of 63.889% with 23 out of 36 embryos. At the developmental day 
E11.5 p.c., 14 from 54 embryos were WT, which accounted for 25.926%. The developmental 
stage of E13.5 p.c. provided a WT frequency of 36.17% (17 out of 47 embryos). The 
developmental age E15.5 p.c. yielded a WT incidence of 19.444% with seven out of 36 
embryos, which proved to be WT. That autocatalyzed embryo with an unknown genotype 
was excluded.  
 
To test whether the obtained genotyping incidences significantly differ from the 
expected Mendelian ratio of 1:2:1, a chi-square test was applied for two cohorts, which were 
divided into an E11.5 cohort and an after-E11.5 cohort. The E11.5 cohort offered the results 
of 14 homozygous, 26 heterozygous and 14 WT embryos. The calculated p-value amounted 
to 0.964, which is not significant. The after-E11.5 cohort offered the following figures: 14 
homozygous, 45 heterozygous and 24 WT embryos. Based on it, the application of the chi-
square test showed a p-value of 0.223, which also was regarded as not statistically significant. 
These data appear to allow different interpretations. Either the timepoint of lethality lies after 
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E11.5 p.c. or the sample size was too small to detect significant differences of genotyping 
incidences.  These interpretations will critically be debated in the discussion part.  
3.2 Whole-mount inspection of  Tm-1a embryos 
In addition to genotyping of embryos all collected embryos were inspected for their external 
morphology at each regarded developmental day. The objective of this approach was to 
detect a putative correlation of the genotype and the occurrence of external peculiarities.  
All genotyped embryos were systematically screened for external aberrancies. Both 
sides of each embryo were evaluated and photodocumented. For each timepoint, a cohort 
of screened embryos resulted, which was identical to the genotyping cohorts for the 
developmental day E13.5 p.c. and E15.5 p.c. For the embryonic age E11.5 p.c., eleven 
embryos from two litters (270.x and 186.x) were photographically acquired. The remaining 
embryos could not be included because of phototechnical reasons.  
3.2.1 Definition criteria of the external-phenotype score 
 
An external phenotype (EP) was observed. Definition criteria (EP criteria) were set up 
(compare table 7). Based on it, an EP score was constructed and applied, which facilitated 
the evaluation of the severity of the EP. The first major criterion is the occurrence of reticular 
telangiectasias (rTEL) in the torso region of the embryonic body, regarded per side. It 
accounts for two EP points per affected side. These rTEL appear as a three-dimensional 
network of sub- and intracutaneous vessels, which are bulged in sections of its transverse 
axis without disconnection to the up- and downstream region of the respective vessel. These 
telangiectatic networks occurred either unilateral or bilateral. That is why the EP score 
awards two points per side, which exposes rTEL. The fact that the three-dimensional 
structure of rTEL is better assessable with the simultaneous occurrence of subcutaneous 
edema (SE), is taken in account with the second major criterion (occurrence of SE), which 
was treated as an additional criterion. It awards one point, in case SE occur in addition to 
3 Results 40 
rTEL. The occurrence of autocatalysis was handled as a criterion of disqualification, because 
autocatalysis is a multifactoral happening that sporadically occurs during embryogenesis. Its 
causative connection to Tm-1a homozygosity can neither be excluded, nor proven. 
Therefore, one minus EP point was assigned marking disqualification. Especially for E13.5 
embryos, one minor criterion (the occurrence of more than four red spots [RS] in the torso 
region of the embryonic body) was additionally set up, because a putative correlation to the 
same etiology of the major criteria could not be excluded in advance. Therefore, it accounted 
for one point in the EP score. RS depict point- or oval-shaped hemorrhagic structures of a 
certain size, contour and colour being localized at the embryonic torso. The size of RS ranges 
from a fixed lower to an upper limit. The lower limit is oriented at the size of the developing 
hair follicles of the future whiskers of the respective embryo. The size of the respective 
eyeball constitutes the upper limit. The shade of red, which is characteristic for RS is defined 
to be a brighter red than the colour of the prominent temporal vessel in one representative 
of each litter. In case the litter was formalin-fixed with the result of oxydated hemoglobin, 
the evaluation of the red colour could not be applied, since methemoglobin is unitary brown, 
which allows no colour distinction. To concern the contour of RS, a more diffusely 
contoured shape depicts the reference compared to rTEL.  
  
Table 8 shows the categories of the EP score. The assignment of zero points was 
categorized as no EP detected (nEPd). The award of two until five points was defined as EP 
detected (EPd), where the principle of concordant correlation between the amount of points 
and the severity of EP lies at hand. The assignment of one point depicts an intermediate type 
(IMT), which lies between both prior mentioned groups. The award of one minus EP point 
was categorized as disqualified. 
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3.2.2 E11.5 embryos 
At the developmental age of E11.5 p.c., eleven embryos were inspected for external 
peculiarities in terms of the pre-defined major and minor criteria of the EP score. Figure 5 
gives a representative visual impression of the external morphology correlated to the 
determined genotype. From two homozygous, three WT and six heterozygous embryos, 
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none showed a pathology suiting the EP criteria. Two embryos were autocatalyzed with a 
known genotype (compare table 9). In this case, one autocatalzed embryo proved to be 
homozygous and the other embryo proved to be WT, where the underlying cause remains 
unclear. As aforementioned, autocatalysis served as a criterion of disqualification, because in 
utero death may routinely occur as a multifactorial happening.  
 
3.2.3 E13.5 embryos 
Figure 6 shows a visual impression of the external morphology of E13.5 embryos. At the 
embryonic day E 13.5 p.c., eight homozygous, 17 WT and 22 heterozygous embryos were 
externally inspected for the occurrence of an EP, where one autocatalyzed embryo proved 
to be homozygous (compare table 10). Among 17 WT embryos, none exposed criteria of 
the EP or the IMT.  
 
Four out of eight inspected homozygous embryos showed an EP, where one embryo 
(257.7) exposed an IMT, which complied with the minor criterion. Two homozygous 
embryos did not expose an EP (nEPd) and one embryo (235.8) was disqualified because of 
external autocatalysis. From 22 regarded heterozygous embryos, 21 showed no detectable 
3 Results 43 
external pathology, where one exposed an EP (218.6 [both sides: rTEL]). In other words, 
from five EPd, four proved to be homozygous, one was heterozygous and none manifested 
a WT genotype. One homozygous IMT was detected.  
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3.2.4 E15.5 embryos 
 
Table 11 shows a brief overview of the observed external peculiarities of the E15.5 cohort. 
An augmentation of rTEL, which were detected in E13.5 embryos, is intensifyingly visible 
in homozygous E15.5 embryos. Four out of six homozygous embryos displayed at least one 
criterion of the pre-defined EP. One homozygous embryo (117.4) exposed no EP that 
followed the definition criteria. One homozygous embryo, which was autocatalyzed, was 
disqualified (106.4). Zero out of 23 heterozygous embryos showed an EP. Zero out of seven 
WT embryos exposed an EP. The genotypical apportionment of four E15.5 embryos, which 
showed an EP, is four homozygous, zero heterozygous and zero WT embryos. A visual 
outline of the external morphology of E 15.5 embryos is given by figure 7. 
3.2.5 Synopsis: categorization of Tm-1a embryos 
In the following the exact EP-point assignment shall be presented, where table 12 shows an 
overview. Four evaluated embryos exposed a severe EP (218.11 [homozygous], 190.4 
[homozygous] and 170.3 [homozygous], 218.6 [heterozygous]), which was scored with five 
EP points that indicate the occurrence of bilateral rTEL in addition to SE. The homozygous 
embryo 756.3 exposed rTEL at both sides, which resulted in four EP points. The 
homozygous embryo 170.5 exhibited rTEL at the left side and SE with three EP points. 
Three homozygous embryos showed a light form of EP that was awarded with two EP 
points, which reflects unilateral rTEL (752.6 [left side], 756.6 [left side] and 190.3 [left side]). 
One homozygous embryo (257.7) exposed more than four RS, therefore, was awarded with 
one EP point, which was classified as IMT. Because of the occurrence of autocatalysis five 
embryos were disqualified (186.3, 270.2, 235.8, 106.2 and 106.4).   
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The genotypical distribution of the occurrence of an EP lies on the part of Tm-1a 
homozygosity, since eight out of nine embryos, which exposed an EP have proven to be 
homozygous, where one embryo was heterozygous. Another striking notion is that among 
all 24 WT embryos, zero exposed an EP. For the timepoint E11.5 p.c., two out of eleven 
embryos showed autocatalysis, which officiated as a criterion of disqualification (compare 
table 7). In the homozygous 11.5 cohort, zero EPd and one nEPd were observed. Regarding 
the homozygous embryos of the E13.5 cohort, four EPd and two nEPd were detected. In 
the E15.5 cohort, four EPd and one nEPd were documented. Under the assumption that a 
correlation between a specific genotype and the EP randomly occurs, one would expect an 
equal distribution of one third per genotype. Applying the chi-square test with the expected 
absolute distribution and the factually aquired EP amount of eight homozygous, one 
heterozygous and zero WT counts, the p-value equals 0.018, which is by conventional criteria 
considered to be statistically significant. Therefore, the occurrence of the EP is significantly 
associated with Tm-1a homozygosity. These data give evidence that Tm-1a homozygosity is 
involved in the occurrence of an EP. Externally visible features, such as edema or alterations 
in the cutaneous surface, are predescribed by a variety of authors serving as the starting point 
of reasonable suspicion for cardiac impairment during embryogenesis (Lin et al. 2012; 
Abdelhamed et al. 2015).  
3.3 Histological assessment of  Tm-1a hearts   
3.3.1 Part I: evaluation of non-ventricular structures  
To investigate if  an impairment of  cardiogenesis in homozygous Tm-1a embryos is 
observable, histological analyses of  the hearts were performed. H.E.-stained sections of  
3 Results 47 
embryonic hearts at three developmental ages (E11.5 p.c., E13.5 p.c. and E15.5 p.c.) were 
systematically evaluated for predefined characteristics, which will be mentioned below. The 
explicit selection of  these timepoints is decisive for the evaluation of  cardiogenesis. Because 
at E11.5 p.c., myocardial development is completed neither in terms of  compaction, nor in 
terms of  trabeculation, it is reasonable to start its evaluation at E13.5 p.c. The histological 
evaluation of Tm-1a hearts was divided in part I (evaluation of non-ventricular structures) 
and part II (evaluation of ventricular structures) for E13.5 and E15.5 hearts.  
For the histological examination at the developmental day E11.5 p.c., all six 
homozygous embryos from four representative litters (270.x, 186.x, 765.x and 763.x) were 
evaluated to be sagittally sectioned and analyzed. This resulted in four out of six potential 
homozygous candidates, where one homozygous embryo (270.2) was excluded, because it 
was autocatalyzed. Here, no litter-internal WT control was available. The other excluded 
embryo (763.7) was unevaluable due to histo-technical issues. The four homozygous 
embryos 186.2, 765.4, 763.2 and 763.9 were included and compared to seven litter-internal 
WT controls (186.7, 765.2, 765.7, 765.8, 763.3, 763.4 and 763.5). For the E13.5 cohort, four 
litters were included with a sum of twelve reviewed embryos, six homozygous ones and six 
WT controls. Litter I (752.x) contributed with two homozygous embryos (752.4 and 752.6) 
and two WT controls (752.8 and 752.9). Litter II (756.x) offered two homozygous embryos 
(756.3 and 756.6) and two WT controls (756.2 and 756.4). Litter III (235.x) yielded one 
homozygous embryo (235.8) and one respective WT control (235.6). Litter IV (257.x) offered 
one homozygous embryo (257.7) and one WT control (257.10). Two candidates had to be 
excluded because of histo-technical and paraffin-embedding issues. For the E15.5 cohort, 
three litters were included with an amount of ten embryos with five homozygous hearts, four 
WT controls and one heterozygous embryo, which served as the control in one litter (litter 
III: 190.x) under reservation. 
  Litter I contributed with two homozygous embryos (170.3 and 170.5) and three WT 
controls (170.7, 170.8 and 170.10). Litter II administered one homozygous embryo (117.4) 
and one WT control (117.1), where litter III offered two homozygous embryos (190.3 and 
190.4) and one heterozygous control (190.1), whose EP exposed no pathologies. It was 
included under reservation, since among five embryos of this litter, no WT embryo was 
obtained. One homozygous candidate (106.4) was excluded because of advanced 
autocatalysis with no distinguishable tissue being left.    
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3.3.1.1 E11.5 hearts  
 
The BC hallmarks the section level I (compare figure 8, pic. A-C). This section enables the 
evaluation of the venous valves (1. rated criterion) with the right atrium (2. rated criterion), 
the morphology of the BC, its myocardial architecture in terms of the question whether a 
high degree of trabecular rarefication is detectable or not (3. rated criterion) and the 
evaluation of surrounding structures (compare table 13). 
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The section level II shows the ECT from both the outflow tract and the atrioventricular 
canal (compare figure 8, pic. D-F). This section level gives insights into the histomorphology 
of the myocardial construction in terms of the evaluation of the trabeculation (3. rated 
criterion), the formation of the ECT that lines the atrioventricular canal (1. rated criterion) 
and the outflow tract (2. rated criterion, compare table 13).  
The common ventricular chamber is the evaluated section level III, which shows a 
marginal zone of the future left-ventricular myocardium in a relatively circular configuration. 
It allows the most undistracted evaluation of trabecular formation among all section levels 
of E11.5 hearts (2. rated criterion, compare figure 8, pic. G-I). Moreover, this level of 
sectioning gives insights into the cavitary morphology of the left atrium (1. rated criterion, 
compare table 13).   
 
Table 13 and figure 8 give overviews of the histological analysis of E11.5 hearts. For 
the section level I, three items were rated in four homozygous specimens and seven WT 
controls, where the rated items were evaluated in each specimen. In case one item was not 
evaluated because of histo-technical reasons, it was excluded from the total amount of 
reviewed embryos, as is indicated by angled brackets in table 13. For the first rated item, all 
homozygous and all WT controls exposed an intact morphology of the venous valves. 
Regarding the second rated item, all specimen showed an intact right-atrial formation. Two 
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out of three homozygous hearts (765.4 and 763.9) revealed rarefied ventricular trabeculation, 
where two out of five WT controls also exposed the former mentioned feature (765.2 and 
763.5). Two WT controls were excluded because of unevaluable sections (186.7 and 765.7). 
The results of the section level II (ECT) show that all eleven embryonic hearts exposed an 
intact lining of the atrioventricular canal and the outflow tract by ECT, independent of their 
genotype. The myocardium in two out of four homozygous specimens (765.4 and 763.9) and 
two out of six WT controls exposed highly rarefied trabeculae (765.2 and 763.5). In section 
level III (common ventricular chamber), all evaluated specimens (three homozygous [182.2, 
765.4 and 763.2] and seven WT hearts) showed an intact morphology of the left atrium. 
Three out of ten specimens (765.4, 765.2 and 763.5) exposed a rarefied trabeculated 
myocardium and five out of seven WT controls exposed a highly trabeculated myocardial 
architecture (186.7, 765.2, 765.7, 765.8, 763.3, 763.4 and 763.5).  
Summarizingly, the reviewed hearts exhibit a fluctuating profile of myocardial 
trabeculation, whereas other cardiac structures expose intact formation. Rarefied 
trabeculation becomes apparent in homozygous and WT hearts, which implied that 
variations in the degree of trabeculation occur physiologically, without obligatory 
pathological significance.  
3.3.1.2 E13.5 hearts  
The aortico-pulmonary spiral septum (APSS) is the hallmark of the section level I (compare 
table 14). The APSS consists of embryonic connective tissue that structurally keeps the 
pulmonary trunk (PT) and the aorta in juxtaposition. This section level was chosen, because 
it reveals many crucial anatomical structures at one glance (compare figure 9, pic. A-D): the 
PT (2. rated criterion), the PDA, the proximal part of the ascending aorta (PAA; 3. rated 
criterion), the configuration of the right-ventricular outflow tract (RVOT; 4. rated criterion) 
and the atrial formation are assessable.  
The AV depicts the section level II (compare figure 9, pic. E-H). This section level 
enables the evaluation of the morphology of the AV (1. rated criterion, compare table 14) 
and the interventricular septum (2. rated criterion).  
The histological hallmark of the section level III is the physiological VSD (pVSD). It 
offers the evaluation of the morphology of the atrio-ventricular ECT and the morphology 
of the pVSD (1. rated criterion, compare table 14 and figure 9, pic. I-L).  
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Table 14 presents the results of the histological analysis of the E13.5 embryos. To 
expound the findings of the section level I (compare figure 9), twelve embryos were rated 
with four items (compare table 14). All four items were targeted on the evaluation of the 
intact morphology of blood-conductive (RVOT, PT and PAA) or tissue-connective (APSS) 
structures. All six homozygous E13.5 embryos exposed a physiological configuration, except 
for two homozygous embryos (752.6 and 756.6) that did not allow the evaluation of the PT, 
because serial sections did not expose it. All WT control hearts exposed an intact 
morphology of the prior mentioned structures. The serial sections of 756.2 did not allow the 
evaluation of the APSS, PT, PAA and RVOT. Serial sections of 752.9 did not enable the 
review of the PT and PAA. Therefore, they were excluded from the assessment.  
3 Results 52 
 
For the section level I, all twelve E13.5 embryos were included for validation. They 
exposed an intact formation of the AV and the interventricular septum (IVS). To present the 
results of the section level III, in four out of six homozygous hearts and in three out of six 
WT controls a VSD was detected (compare figure 9).  
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Deductively, in E13.5 embryos histocardial structures such as vasculature and the APSS 
showed no signs of impairment. Since septation is expected to be completed around E14.5 
p.c., the detection of VSD in both homozygous and WT control hearts was regarded as 
physiological.   
3.3.1.3 E15.5 hearts  
 
The hallmark of the section level I is the pulmonary valve (PV) that consists of three cuspids 
(anterior, left and right cuspid) and connects the RVOT with the PT. Furthermore, the aortic 
arch and the PDA, which connects the PT with the distal part of the aortic arch (dAA), were 
assessed. The evaluation of the area of the former APSS was also aspired (compare figure 
10, pic. A-D).  
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The section level II is represented by the AV. The formation of the aortic leaflets and 
the fibrous anulus were evaluated (compare figure 10, pic. E-H).  
The AVV hallmark the section level III (compare figure 11). All four chambers of the 
heart are assessable. The AVV were examined regarding connection to chordae tendinae and 
formation of the atrioventricular cuspids. Potential intercavitary communications are 
assessable in terms of a potential VSD, since septation is physiologically completed around 
E14.5 p.c.  
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Table 15 gives an overview of the histological analysis of the transverse sections of ten 
E15.5 hearts. To regard the first two section levels, all included E15.5 embryos exposed an 
intact AV and PV formation, an adequately formed PDA, an intact morphology of the 
RVOT, an adequate formation of the PAA and a physiological formation of both atria. One 
homozygous embryo (117.4) was excluded, because of histo-technically unevaluable sections. 
In section level III, ten out of ten embryonic hearts exhibited an intact formation of the 
AVV, independent of the genotype. To concern the rated VSD-detecting item, three out of 
five homozygous embryos showed a VSD (190.3, 190.4 and 170.3). Two specimens exposed 
no VSD (170.5 and 117.4). All controls showed no VSD (compare table 15).  
 
As an excursus, the cutis was histologically assessed in E13.5 and E15.5 embryos 
(compare figure 12). In contrast to cutaneous hemorrhages (such as RS), telangiectasias 
expose an intact endothelial border, which is microscopically demonstrated in figure 12 (pic. 
A) and macroscopically leads to the sharp contour of rTEL. This notion of intact vessel walls 
further supports the hypothesis that circulatory congestion induces EP occurrence. The 
representative litter-internal WT controls showed no histological or macroscopical signs of 
congestive vessels (compare figure 12, pic. B). 
3.3.2 Part II: evaluation of ventricular structures 
The histological assessment of E13.5 and E15.5 hearts offered the impression of a differing 
myocardial structure in terms of a varying width of the vCZ. In part I, all cardiac structures, 
except for the ventricular myocardium, were examined in homozygous and control hearts. 
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Part II of the histological assessment will evaluate ventricular structures by width 
quantification of the vCZ in homozygous hearts compared to WT controls in E13.5 and 
E15.5 embryos. Thereby, the question will be addressed, whether Tm-1a homozygosity can 
be nominated as an influencing factor that affects the formation of the myocardium during 
cardiogenesis in Tm-1a embryos.   
To generate a representative cohort of analyzed hearts, all homozygous and WT 
embryos of part I were evaluated for the width measurement of the vCZ in the RV and the 
LV, respectively. For the E13.5 cohort, the litters 752.x, 756.x, 235.x and 257.x were included 
with a total number of six homozygous and six WT embryos. For the E15.5 cohort, the 
litters 170.x and 117.x were included with three homozygous embryos and four WT controls. 
The E15.5 litter 190.x was excluded from part II, because it offered no WT embryo. Tm-1a 
heterozygosity was not enough to serve as control in part II, because the non-affection of 
the myocardial structure could not be assured in advance. Shortly summarized, four 
sequential section levels were analyzed per embryo, where one section slide showed both 
ventricles, whose perpendicular width of the vCZ was measured in five fixed positions (apical 
to basal). In total, an amount of 20 measuring values resulted per ventricle of each specimen. 
The respective average was calculated. An unpaired, two-sided, homoscedastic Student’s t-
test was performed, which compared the calculated means of the homozygous samples to 
the WT-control means for each cohort.     
3.3.2.1 E13.5 hearts 
Table 16 visualizes the descriptive statistics of the width measurement of the vCZ in E13.5 
hearts. Litter I (752.x) offered two homozygous specimens (752.4 and 752.6), whose right-
ventricular widths averaged out at 37,199 µm (752.4) with a SD of 8.463 µm and 18.961 µm 
(752.6) with a SD of 4.013 µm. The LV means of CZ width of 752.4 and 752.6 depicted 
51.516 μm (with a SD of 8.317 µm) and 29.521 μm (with a SD of 6.998 µm). Two WT 
embryos were included and measured (752.8 and 752.9). The right-ventricular compact-zone 
(rvCZ) means amounted to 34.028 µm and 44.512 µm with a SD of 7.978 µm (752.8) and 
18.856 µm (752.9). The LV mean of 752.8 (WT) averaged out at 40.611 µm with a SD of 
8.796 µm. The WT specimen 752.9 showed a LV mean of 50,201 µm with a SD of 19.111 
µm. Litter II exhibited the inclusion of two homozygous embryos (756.3 and 756.6) with a 
respective mean of the rvCZ width of 17.058 µm (and a SD of 6,647 µm) and 19.525 µm 
(with a SD of 6,740 µm). The homozygous embryo 756.3 offered the mean of left-ventricular 
compact zone (lvCZ) of 28.186 μm with a SD of 9.864 µm, where embryo 756.6 shows a LV 
mean of 20.268 μm with a SD of 8.240 µm. For the WT control 756.2, the mean of the rvCZ 
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width was 25.403 µm with a SD of 15.769 µm. The averaged width of the second WT control 
756.4 was 55.916 µm with a SD of 21.348 µm. The mean of the lvCZ width of 756.2 (WT) 
depicted 33.138 µm with a SD of 12.043 µm. The LV mean for 756.4 accounted for 53.011 
µm with a SD of 8.789 µm. In litter III, the mean of the rvCZ width of homozygous embryo 
235.8 averaged out at 39.978 µm with a SD of 18.118 µm, where the RV mean of the WT 
embryo 235.6 amounted to 72.503 µm with a SD of 33.572 µm. The lvCZ mean of 41.051 
μm (SD 9.184 µm) was calculated for the homozygous embryo 235.8 with a WT control LV 
mean (235.6) of 77.339 μm (SD 13.569 µm). In litter IV, the homozygous embryo 257.7 
exhibited an average of rvCZ width of 44.714 µm with a SD of 15.559 µm. The WT embryo 
257.10 showed a RV width mean of 59.319 µm (SD 19.646 µm). The lvCZ mean of the 
homozygous embryo 257.7 was 62.674 μm (SD of 22.711 µm). The WT control (257.10) 
showed a LV mean of 84.723 μm with a SD of 13.819 µm.  
Table 16 shows the results of an unpaired two-sided, homoscedastic Student’s t-test, 
separately performed for the RV and LV. The p-value equals 0.054 for the RV and 0.127 for 
the LV, which are both regarded as not statistically significant. This implies that the 
influencing factor Tm-1a homozygosity has no significant effect on the width of vCZ in 
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E13.5 hearts, which is one leading parameter for the evaluation of ventricular compaction. 
In other words, these data give evidence that ventricular compaction is not significantly 
affected by Tm-1a homozygosity in E13.5 hearts. Furthermore, figure 13 visualizes the 
relationship of the genotype and the width of the vCZ in the E13.5 cohort.   
 
3.3.2.2 E15.5 hearts 
Table 17 shows an overview of the descriptive statistics for the E15.5 cohort. Two litters 
(170.x and 117.x) were recruited with a total amount of three homozygous embryos and four 
WT embryos. In litter I, two homozygous embryos (170.3 and 170.5) were measured with a 
RV mean of 54.021 μm (SD 32.609 µm) and 78.498 μm (SD 47.098 µm). The RV mean of 
WT specimen 170.7 averaged out at 148.715 µm with a SD of 40.270 µm. The WT specimen 
170.8 showed a RV mean of 168.105 µm with a SD of 18.998 µm. The RV mean of the WT 
embryo 170.10 amounted to 171.192 µm (SD of 35.300 µm). For the LV in litter I, the mean 
for 170.3 averaged out at 120.121 μm with a SD 26.873 µm. For the homozygous specimen 
170.5, the LV mean amounted to 130.854 μm with a SD of 24.026 µm. The WT specimen 
170.7 showed a LV mean of 192.978 µm with a SD of 29.781 µm. The embryo 170.8 exposed 
a LV mean of 165.390 µm with a SD of 14.478 µm. WT embryo 170.10 showed a LV mean 
of 202.077 µm with a SD of 35.495 µm. In litter II, the RV mean of the homozygous embryo 
117.4 depicted 107.563 μm with a SD of 17.932 µm, where the RV mean of 117.4 (WT 
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control) averaged out at 175.171 µm with a SD of 26.457 µm. In litter II, the lvCZ mean of 
the homozygous embryo 117.4 depicted 135.620 μm with a SD of 38.535 µm. The LV mean 
of the WT control 117.1 amounted to 185.516 μm with a SD of 25.745 µm.  
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Also, for the E15.5 cohort an unpaired two-sided, homoscedastic Student’s t-test was 
performed to address the question whether the width of vCZ in homozygous specimens 
significantly differs from those in WT controls. Table 17 shows the calculated p-values. Both 
rounded p-values equal 0.002. Therefore, p-values were regarded as statistically significant. 
These data imply that the width of the vCZ is significantly reduced compared to WT controls 
in the E15.5 cohort. Thus, biventricular non-compaction can be demonstrated. Therefore, it 
seems conceivable that Tm-1a homozygosity impedes the developmental process of 
myocardial compaction. Figure 14 shows the correlation of the compact-zone width and the 
genotype in the E15.5 cohort.    
3.3.3 Synopsis: histological assessment of Tm-1a hearts 
The results of the histological analysis of embryonic hearts at three developmental timepoints 
showed no differences in the following items: morphology of valves (venous valves in E11.5 
embryos and atrioventricular and semilunar valves in E13.5 and E15.5 embryos), the outflow 
tracts, the ECT lining of the atrioventricular canal and the formation of blood-conductive 
vasculature (PT, PAA and PDA). The VSD occurrence was documented in three out of five 
homozygous E15.5 embryos, where five out of five WT controls showed no VSD. In part 
II, biventricular non-compaction was proven to occur in homozygous E15.5 hearts. In E13.5 
hearts, the vCZ in homozygous hearts was not significantly reduced compared to WT 
controls.  
3.4 Correlation of  the external-phenotype score and the ventricular 
reduction ratio  
 
After having presented the results of measuring the vCZ width in twelve E13.5 and seven 
E15.5 hearts, the connection of chapter 3.2 and 3.3 will be promoted to address the question 
whether the occurrence of an EP can be traced back to differences in the respective CZ 
width.  
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The ventricular reduction ratio (vRR) was calculated to assess the degree of width 
reduction in homozygous embryos that were EP scored and whose hearts were measured 
(compare figure 15). The vRR is a dimensionless figure that reflects the degree of ventricular 
non-compaction. The vRR is calculated by subtraction of the following ratio from one: the 
ratio is calculated by dividing the mean of the CZ width of one homozygous specimen by 
the total mean of the WT control(s) of the same litter (compare figure 15). The bigger vRR, 
the higher the degree of non-compaction can be stated.  
Table 18 shows an overview of the EP-point assignment and the calculated vRR for the 
RV and the LV in the E13.5 and E15.5 cohort, which is further visualized in figure 16. In 
the following, the vRR of the E13.5 cohort will be presented. Because of histo-technical 
reasons, the litter of the embryos that were EP scored with five points (218.6 and 218.11) 
could not be included in the histological assessment. Still, both embryos are listed. Being 
assigned with four EP points, because of bilateral rTEL, the homozygous embryo 756.3 
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featured a right-ventricular reduction ratio (rvRR) of 0.580 and a left-ventricular reduction 
ratio (lvRR) of 0.346. The homozygous embryo 752.6 featured unilateral rTEL, therefore, 
was asssigned with two EP points. It exhibited a rvRR of 0,517 and a lvRR of 0.350. The 
homozygous embryo 756.6 was assigned with two EP points, because of unilateral rTEL. 
 
It offered a rvRR of 0.520 and a lvRR of 0.529. Exhibiting an IMT with one EP point, 
the homozygous embryo 257.7 featured a rvRR of 0.246 and a lvRR of 0.260. The 
homozygous embryo 752.4 that exposed no EP (zero EP points) offered a rvRR of 0.053 
and a lvRR of 0.135. Because of external autocatalysis, the homozygous embryo 235.8 was 
disqualified. Still, it offered inner organs that were histologically assessable despite of 
progressive external autocatalysis. Its rvRR depicted 0.449 and the lvRR accounted for 0.469. 
To regard the E15.5 cohort, two homozygous embryos were assigned with five EP points, 
which mophologically reflects bilateral rTEL with additional SE (190.4 and 170.3). The 
homozygous embryo 190.4 was excluded from width measurement as previously mentioned, 
because no WT control was available within the litter 190.x. The vRR of the second 
homozygous E15.5 embryo that was EP scored with five EP points (170.3) amounted to 
0.668 (rvRR) and 0.357 (lvRR). The homozygous embryo 170.5 was EP scored with three 
EP points and featured a rvRR of 0,517 and a lvRR of 0.3. The homozygous embryo that 
exposed no EP (117.4) offered a rvRR of 0.386 and a lvRR of 0.269. Progressed autocatalysis 
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frustrated histological assessment of the heart in two homozygous embryos (106.2 and 
106.4). Figure 16 shows the correlation of the respectively assigned EP score and the 
respective vRR in the E13.5 and the E15.5 cohort. To consider the rvRR from two EP points 
upwards, a tendency of positive correlation can be assumed: The higher the rvRR, the severer 
the EP. For the LV no positive regression could be concluded, neither in the E13.5, nor in 
the E15.5 cohort. 
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4 Discussion 
The objective of this study was to elucidate potential molecular machanisms that lead to 
HLHS. The candidate gene KIAA00182 (analogue to Gse-1 in mice), which was found to 
be de novo mutated in a child that suffered from HLHS, was hypothesized to be involved in 
the pathogenesis of HLHS. In addition to this, embryological lethality of homozygous Tm-
1a mice of the Gse-1 mouse model was proven to occur in a previously performed study 
with a g-power of 99.999% (Alnour 2016). The aim of this study was to determine the 
timepoint of embryonic lethality and to identify a putative cardiac phenotype of homozygous 
Tm-1a embryos of the knockout-first mouse line. An established method to detect the 
timepoint of embryonic lethality is to determine the genotypical incidence at consecutive 
embryonic ages. In this study, embryonic cohorts at three developmental timepoints were 
genotyped. The selection of the embryonic ages of E11.5 p.c., E13.5 p.c. and E15.5 p.c. was 
carried out, because the exact timepoint of in utero death of homozygous Tm-1a embryos 
was hard to anticipate without vanguard knockledge on this field. Therefore, a certain 
timeslot was chosen, where cardiogenesis in its early but also later events was covered. Based 
on the genotyping results, homozygous Tm-1a embryos start to die after E11.5 p.c. A decline 
of genotypical incidence was observed, which started to emerge at E13.5 p.c and augmented 
at E15.5 p.c. This fact appears to reflect the onset of developmental impairment of 
homozygous embryos. The genotypical incidences of E13.5 p.c. until E15.5 p.c. offered no 
significant p-values, which may have occurred because of different reasons. Either the 
incidence of Tm-1a homozygosity significantly decreases after E15.5 p.c., which indicates 
that homozygous embryos die after E15.5 p.c., or the p-value of the after-E11.5 cohort was 
not significant, because the sample size was too small to detect a difference of the acquired 
and expected incidences. The calculated g-power of each cohort must be considered, when 
the evaluation of its significance is aspired. The E13.5 and E15.5 cohorts offered a g-power 
of only around 33%, which indicated that a type-II error might be commited in 67% of the 
cases (type-II error: eventhough a real difference lies at hand, the nullhypothesis is mistakenly 
affirmed), which results from too small sample sizes.  
The small genotyping sample size that led to small g-power values represents one 
limitation of this study. The smaller the differences that are aspired to be detected, the bigger 
the sample size must be to achieve a satisfactory g-power, such as 80%. As an important 
future outline, larger cohorts should be pursued to achieve higher g-power values. In addition 
to that, later developmental timepoints (such as E18.5 p.c.) must be investigated, since the 
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homozygous incidence at birth (E19.5 p.c.) is 0%. Therefore, a dramatical decline of 
incidence should be detectable between E15.5 p.c. and the time of birth. 
Looking at the genotyping results for the WT and heterozygous embryos, certain 
discrepancies became apparent. While the expected Mendelian ratio of 50% was 
approximately observed for Tm-1a heterozygosity for the embryonic ages E11.5 p.c., a clear 
deviation from the expected genotypical apportionment was found for E15.5 p.c. One would 
expect that the portion of genotypical gain for heterozygous and WT specimens augments 
in the ratio of 2:1. In this case, the homozygous incidence was reduced by around 9%. 
Therefore, it would have been expected that the heterozygous incidence rises around 6% and 
WT gains 3%. So, a total incidence of 56% for heterozygous and 28% for WT should have 
been traceable. Instead of this, the incidences were around 64% for heterozygous and about 
20% for WT.  Since the WT genotype is characterized by the absence of the second amplicon 
of 127 bp, which is present in heterozygous specimens, sporadic cases of contamination of 
specimens must be assumed.  
To conclude the onset of the embryonic phenotype, the results of genotyping, whole-
mount evaluation and histological analysis were synoptically regarded. The results of the 
external morphology assessment of Tm-1a embryos gave definite evidence that Tm-1a 
homozygosity is highly implied in the occurrence of a so-called EP. At E13.5 p.c., 
homozygous Tm-1a embryos expose external aberrancies, which were aspired to be 
systematically assessed by an EP score. It was intended to enable a genotype-independent 
detection of abnormalities of the external morphology. Therefore, the application of the EP 
score was a primary blinded assessment of external features. The major criteria of the EP 
score were characterized by the occurrence of rTEL and SE. These external aberrancies 
deteriorated in their severity in the E15.5 cohort compared to the E13.5 cohort. With an 
increasing age, the fraction of those homozygous embryos that expose an EP increased.  In 
the E15.5 cohort, 80% of homozygous embryos showed an EP. The fact that one 
homozygous E15.5 embryo (20%) was scored as nEPd reflects the diagnostical imprecision 
of the EP score. Continuative studies of the Gse-1 project have shown that Gse-1 knockout 
embryos expose an impaired hematopoesis, which majorly takes place in the hepatic 
primordium during embryogenesis. Because of this, homozygous embryos exposed anemia 
and as a result of impaired hematopoesis a paler hepatic region, which is even retrospectively 
visible in homozygous Tm-1a embryos. Taking this important finding into account, the 
major criteria of the EP turn out to be incomplete. The minor criterion of RS even appears 
of marginal importance, since its relevance could not be asserted. The fact that 
groundbreaking findings often cannot be anticipated in advance is reflected by a myriad of 
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clinical scores and classifications that found posterior modification. This principle can also 
be applied here, to the first draft of the EP score. As a future outline, a modified version of 
the EP score (modified EP score) should be considered that handles the paleness of the 
hepatic region, which gleams through the embryonic cutis below the right costal arch, as one 
further major criterion. By application of the modified EP score, that one homozygous E15.5 
embryo (117.4), which seemingly exposed no EP, would also have been detected as 
pathological, since it exposed a paler hepatic region compared to non-homozygous litter 
mates.  
A significant biventricular non-compaction and the increased occurrence of VSD of Tm-
1a homozygous hearts were proven to occur at E15.5 p.c., where no significant difference in 
the degree of ventricular compaction in homozygous embryos compared to WT controls 
was shown at E13.5 p.c. This finding constitutes the first description of a cardiac phenotype 
in the Tm-1a knockout-first mouse line. Therefore, it depicts one major discovery in the 
quest of deciphering, why Tm-1a homozygous embryos die. Taken for itself, the cardiac 
phenotype is insufficient to explain embryonic lethality of Tm-1a homozygosity. Future 
studies will tie up to these findings.   
 Furthermore, the tendency of a positive correlation of the EP score and the rvRR was 
assumed.  The vRR is a dimensionless value that is reflecting the degree of ventricular non-
compaction. By regression of the scored EP and the vRR of the respective embryo, a rvRR-
threshold of around 50% can be hypothesized, at which embryos start to expose an EP (two 
EP points or more). Regarding the lvRR, no obvious correlation was asserted, which appears 
contradictory to the results of biventricular non-compaction in E15.5 embryos. As a future 
outline, further improvement into the design of the vRR should be undertaken to stratify its 
diagnostical virtue. Eventhough, biventricular non-compaction only was proven to 
significantly occur in the E15.5 cohort, the vRR calculation involved also the homozygous 
embryos of the E13.5 cohort. Here, the developmental tendency of an emerging non-
compaction in earlier timepoints than E15.5 p.c., such as E13.5 p.c., appears to be hinted, 
which even became qualitatively visible in the histological assessment of homozygous E13.5 
hearts. Eventhough, quantitative analysis did not prove biventricular non-compaction in 
homozygous E13.5 specimens, the onset of myocardial impairment of the CZ can be 
hypothesized to occur earlier than E15.5 p.c., such as E14 p.c. 
The notion that Tm-1a embryos expose external signs of congestion because of 
cardiogenetic impairment seems pathophysiologically reasonable. In this case, cardiac 
impairment is constituted by biventricular non-compaction and the incidence of VSD at the 
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age E15.5 p.c. These aberrancies cause circulatory congestion that becomes externally visible 
in the manifestation of SE and rTEL. These teleangiectatic lesions were histologically 
verified. They exposed intact vessel walls.  
By means of statistical analysis, it was proven that the width of the vCZ is significantly 
reduced in homozygous E15.5 embryos in both ventricles. For the statistical analysis by 
means of an unpaired two-sided, homoscedastic Student’s t-test the comparison of the 
calculated width means of homozygous and WT controls was ensured, since a non-affection 
of heterozygous vCZ could not be excluded in advance. Therefore, the E15.5 litter 190.x, 
which offered three homozygous and two heterozygous embryos, was excluded from the 
quantitative assessment of the width of the vCZ in part II of chapter 3.3. In contrast to that, 
this litter was used for the qualitative visualization of the histological results in part I of 
chapter 3.3, since the technical quality of this litter in the process of methodological 
reprocessing was – compared to other pairs of homozygous specimens and controls – the 
best. Therefore, the histological pictures of chapter 3.3, which utilized mostly 190.x for E15.5 
p.c., may be considered as representative under reservation, since the quantitative evaluation 
of the myocardium was restricted to part II.      
After having pointed out the weakness of the EP score above, primary considerations 
that led to the first draft of the EP score shall be mentioned. The morphologies of E11.5, 
E13.5 and E15.5 embryos were inspected, where the EP was defined by morphological 
criteria. The EP score consisted of two major criteria, which defined the EP. They were 
differingly emphasized with points due to the following factors. The occurrence of rTEL per 
side was awarded with two EP points. This contributed to the fact that an embryo, which 
exposed bilateral rTEL, automatically was scored higher than an embryo that exposed 
unilateral rTEL. By this, the importance of the phenomenon of rTEL for the EP was pointed 
out. The following notions support the presumption of the congestive nature of rTEL. The 
histological inspection of rTEL in homozygous E13.5 and E15.5 embryos compared to litter-
internal WT controls revealed the intact vessel border with no egression of erythrocytes in 
the surrounding connective tissue. The intactness of the vessel walls defines telangiectatic 
lesions. The macroscopically sharp contour of rTEL, the progredient generalization of rTEL 
regarded from E13.5 p.c. to E15.5 p.c. and the impression of a three-dimensional vessel 
network supported the etiology of rTEL to be congestive. In other words, if an embryo was 
classified as EPd, it had to expose rTEL at least at one side of the embryonic body. The sole 
occurrence of SE was counted as unsufficient to be considered as an EP defining event 
because of the following notions. The evaluation of SE is more error-prone than the 
assessment of rTEL. Therefore, it was handled as one additional major criterion. Especially 
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in E11.5 and E13.5 embryos, whose cutis exposes no proper stratum corneum yet, the impact 
of accidental storage in fluids that potentially change the extent of the SE (such as 4%-PFA) 
cannot absolutely be excluded. Another factor, which potentially causes bias in the evaluation 
of SE is of technical nature and depicted by the fact that the recognition of SE highly depends 
on the right exposure to light during the photographical aquisition of each embryo. The 
photodocumentation of SE was less error-prone in E15.5 embryos, which is caused by an 
advanced development of the stratum corneum of the cutis that detains liquid impairment. 
Because of all these factors, the occurrence of SE was handled as a major criterion, since its 
correlation to cardiac congestion is highly implied in literature. If one embryo would have 
exposed SE without rTEL, it would not have been awarded with one point, because of the 
above-mentioned biasing factors, which would have led to wrong-positive counts. 
Interestingly, this theoretical case did not occur once, which adds to the primary importance 
of rTEL. With the award of EP points, the degree of severity of the EP was classified, where 
the assignment of five EP points indicated the most severe form of EP, which implied 
bilateral rTEL and the additional occurrence of SE. This case occurred four times among 95 
evaluated embryos (eleven E11.5, 47 E13.5 and 37 E15.5 embryos). The lightest form of EP 
with the award of two EP points occurred three times. The cases of the award of three and 
four EP points occurred once, respectively. While evaluating E13.5 embryos, another 
phenomenon became apparent, whose appearance was included in the definition criteria of 
the EP (the occurrence of more than four RS). Because of the lacking final formation of the 
stratum corneum with a high extent of cutaneous transparency, the external morphology (of 
E13.5 embryos) was highly characterized by a variety of red structures (cutaneous vessels), 
blood-egressive formations (diffuse hemorrhages), point-shaped configurations (RS) and 
further phenomenons (erythrocytes-contaminated cutaneous surfaces). Among all these 
phenomenons with likely different etiologies, the lowest common denominator between the 
EP and the variety of red structures had to be determined, because a potential etiological 
connection could not be excluded in advance. The fact that in chapter 3.2 many RS items 
had to be defined reflects the high degree of uncertainty that surrounds this minor criterion, 
which aspires to distinct betweeen a relevant item and mere diffuse hemorrhagic structures, 
which resemble background noise. The possibility of the occurrence of traumatic 
hemorrhages is higher in acral regions of the embryonic body, because during emryonic 
dissection, the head or the limbs were accidentally used to be pulled with the forceps to 
separate the embryo from the amniotic sac and the rest of the maternal uterus. Therefore, 
only the torso localization was regarded for counting RS. The threshold of four is an empiric 
figure that helps in the distinction of embryos that expose a higher amount of RS. It underlies 
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an artificial construction of the threshold, where the two major criteria featured less insecure 
characteristics that resemble the principle of a visual diagnosis. These discrepant factors were 
regarded, while designing the minor criterion of the EP score. It resulted in the award of one 
EP point to those embryos that exposed more than four RS on one side of the embryonic 
body. It accounted for the IMT that neither belongs to the group of EPd, nor nEPd. In other 
words, the mere occurrence of more than four RS was not enough to detect an EP. This 
aspect finds further support in the fact that the coincidence of the major and minor criteria 
did not occur in one single case, which putatively indicates an independent etiology. As 
aforementioned, in ongoing studies the minor criterion of RS has found no noteworthy 
relevance. One criterion of disqualification was introduced, which was awarded with one 
minus point: autocatalysis that represented in utero death. To regard the degree of 
autocatalysis, great differences became apparent. Where some autocatalyzed embryos 
exposed such an advanced extent of autocatalysis that genotyping proved unsuccessful 
because of DNA decay (106.2), other autocatalyzed embryos were genotypable and even 
histologically assessable with quantifiable cardiac structures, such as the histologically 
included E13.5 embryo 235.8. All in all, autocatalysis is an erratic event during 
embryogenesis. To concern all five cases of autocatalysis in the E11.5, E13.5 and E15.5 
cohorts, three embryos were homozygous, one proved to be WT and one remained with an 
unknown genotype. Whether autocatalysis is part of the homozygous phenotype can neither 
be proven nor completely be excluded, because of the superimposing fact of routine in utero 
death and the small sample size. Therefore, it was designated as disqualifying criterion. Thus, 
the EP score turned out to be a coding system that simultaneously expressed a certain 
combination of phenomena and enabled a genotype-independent classification of the 
external morphology of Tm-1a embryos.  
The onset of the EP was observable at E13.5. Therefore, the E13.5 and E15.5 cohort 
will be regarded in the following. Eight out of nine embryos that exposed an EP were 
homozygous and one was heterozygous. To regard the WT embryos, zero out of 24 embryos 
showed an EP. To consider all 14 homozygous embryos, eight of them exposed an EP (four 
from the 13.5. and four from the E15.5. cohort), three showed no EP (two of the E13.5 and 
one of the E15.5 cohort), one embryo was accounted as IMT and two embryos were 
disqualified because of autocatalysis. As mentioned above, the modified EP score would 
have detected that one homozygous E15.5 embryo that seemingly showed no EP, since it 
exposed a paler hepatic region. In analogy to this revision, also those two homozygous E13.5 
embryos (752.1 and 752.4), which were nEPd classified, exposed a paler hepatic region, 
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which serves as a sign of impaired hematopoesis in the hepatic primordium that results in 
anemia.  
Certain aspects point at the notion that the cardiac phenotype occurs as a secondary 
event. Hemodynacis are commonly considered to play an important role in cardiogenesis. 
The process of compaction is highly dependent on hemodynamics during development. 
Interestingly, responsiveness to shear stress was shown for many transcription factors, such 
as the superfamily of transforming growth factors β (TGF-β) and the BMP endothelial 
regulator, which are implied in EndMT (Poelmann and Gittenberger-de Groot 2018). The 
hypothesized implication of Gse-1 in EndMT constituted the reasonable suspicion for 
homozygous Tm-1a embryos to expose a cardiac phenotype. In contrast to adult hearts, both 
ventricles play an utmost important role during embryogenesis in the support of systemic 
circulation and the maintenance of growing hemodynamical requirements. The fact that 
biventricular non-compaction occurs in homozygous Tm-1a embryos at E15.5 p.c. appears 
to reflect that non-compaction results from a still unknown triggering factor, which 
accordingly affects the more required part of the myocardium. The heterogenous picture of 
the EP and the paucity of one definite timepoint of embryonic lethality at early ages of 
cardiogenesis further support this notion that cardiac non-compaction appears not to be the 
primary result of a gene knockout. A primary triggering factor is putatively necessary for the 
developing heart of homozygous Tm-1a mice to correspond to it in such dramatical way. To 
a certain degree, the results of this thesis reflect the decisiveness of the complex 
pathogenetical interplay, which is commonly assumed to occur in CHD. In several previous 
studies, hypoxia was described to be one major-triggering factor for myocardial non-
compaction in addition to further severe congenital heart defects (Kenchegowda et al. 2014). 
The experimental production of hypoxic conditions in the developing embryos of a certain 
mouse model at early stages of cardiac development, such as E9.5 p.c., induced severe cardiac 
malformations like DORV or conotruncal defects. The induction of hypoxia at later 
timepoints, such as E13,5 p.c., showed no effects on cardiogenesis (Kenchegowda et al. 
2014). Physiologically, embryonic hearts expose mechanisms to cope with hypoxia. The 
occurrence of the cardiac phenotype might secondarily occur, as a response to anemia-
conditioned hypoxia during a hypoxia-sensitive phase of myocardial cardiogenesis.  
The results of this thesis remain on a relatively descriptive level. It cannot exactly be 
answered how the Tm-1a allele is involved in the pathogenesis of biventricular non-
compaction at E15.5 p.c. Still, these results enable further investigations as a groundwork to 
understand the specific mechanisms that lead to embryonic lethality of homozygous Tm-1a 
embryos. As an important future outline further mechanistic insights of Gse-1 will be 
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aspired, such as identifying the expression pattern of Gse-1 in Tm-1a hearts by means of lac-
Z staining and continuative investigation of the mouse lines Tm-1b, -1c and -1d.  
The pathogenetical model that congenital heart disease occur as a result from a 
multifactorial happening is commonly accepted. Environmental factors face genetical 
predispositions that, furthermore, meet still unknown events, which finally may result in such 
dramatical and life-threatening diseases such as HLHS. Gittenberger-de Groot and 
colleagues pointed out that transgenic animal models allow insights, which - in combination 
with human pathology - lead to a better understanding of congenital heart diseases 
(Gittenberger-de Groot et al. 2005). ‘From bench to bedside’ is a bon mot that expresses the 
translational quest as an ideal giuding theme of medical basic research. With this thesis, the 
groundwork for further mechanistic insights of the molecular function of Gse-1 during 
embryo- and especially cardiogenesis was set that enables the identification of translational 
approaches to treat HLHS patients.  
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Introduction and objective of this study: HLHS is classified as a cyanotic heart disease, which 
accounts for 25% of all CHD mortalities. It is the leading cause of death in infants under the age of 
one year (Gillum 1994; Bradley 1999). HLHS is multifactorially caused. One human candidate gene 
called KIAA00182 (Gse-1 in mice) was hypothesized to be implied in the pathogenesis of HLHS 
because of a) a de novo mutation of it, which was found in a child suffering from HLHS, and b) the 
documented lethality of homozygous Gse-1 mice by the age of three weeks. The objective of this 
study was to determine the timepoint of embryonic lethality of homozygous Tm-1a embryos and to 
identify a putative cardiac phenotype.  
Experimental methods: The genotype of embryos at three embryonic ages (E11.5 p.c., E13.5 p.c. 
and E15.5 p.c.) was determined by PCR. The external morphology was inspected and assessed with 
a scoring system (external-phenotype score), which allowed a severity classification of external 
aberrancies. In two parts, the hearts of Tm-1a embryos were histologically analyzed, where part I 
focussed on the evaluation of non-ventricular structures. In part II, the quantitative assessment of 
the ventricular compact zone was performed. The quantification was further substantiated by the 
calculation of a ventricular reduction ratio, which reflects the degree of myocardial non-compaction. 
Regarded for E13.5 and E15.5 embryos, the correlation of the external-phenotype score and the 
ventricular reduction ratio was promoted.  
Results: Genotyping Tm-1a embryos of three developmental ages showed a decline of Tm-1a 
homozygosity from 25.92% to 16.67% with an increasing age. By whole-mount inspection of Tm-1a 
embryos, the occurrence of an external phenotype was documented, whose major characteristics were 
reticular telangiectasias and subcutaneous edema. It was shown that its occurrence is highly associated 
with Tm-1a homozygosity. Histological assessment of embryonic hearts showed a significant 
biventricular non-compaction in homozygous E15.5 hearts, whereas in homozygous E13.5 embryos 
no significant non-compaction occurred.  
Conclusion: Homozygous Tm-1a embryos start to die after E11.5 p.c., where the onset of 
developmental impairment appears to start between E12.5 p.c. and E13.5 p.c. In homozygous Tm-
1a embryos, a time slot of embryonic lethality, which putatively starts to emerge between E13.5 p.c. 
and E16.5 p.c., seems pathogenetically conceivable. The discovery of biventricular non-compaction 
in homozygous E15.5 hearts constitutes the first description of a cardiac phenotype of the Gse-1 
mouse line, which was identified as one element of aberrant pathogenesis that further appears to 
contribute to embryonic lethality of Tm-1a homozygosity. The paucity of one definite timepoint of 
embryonic lethality and the heterogenous picture of the external phenotype support a suspected 
secondary etiology of the cardiac phenotype. In future studies, still unknown primary causative 
factors must be identified.        
6 List of references 73 
6 List of  references 
 
Abdelhamed ZA, Natarajan S, Wheway G, Inglehearn CF, Toomes C, Johnson CA, Jagger DJ 
(2015): The Meckel-Gruber syndrome protein TMEM67 controls basal body positioning 
and epithelial branching morphogenesis in mice via the non-canonical Wnt pathway. Dis 
Model Mech 8, 527–541 
Aiello VD, Ho SY, Anderson RH, Thiene G (1990): Morphologic features of the hypoplastic left 
heart syndrome--a reappraisal. Pediatr Pathol 10, 931–943 
Allen RH, Benson CB, Haug LW (2005): Pregnancy outcome of fetuses with a diagnosis of 
hypoplastic left ventricle on prenatal sonography. J Ultrasound Med 24, 1199–1203 
Alnour F: ‘Knockout-first’ mouse model as a biological tool to study the role of KIAA0182 gene in 
hypoplastic left heart syndrome. Med. diss. Göttingen 2016 
Anderson RH, Wilkinson JL, Becker AE (1978): The bulbus cordis--a misunderstood region of the 
developing human heart: its significance to the classification of congenital cardiac 
malformations. Birth Defects Orig Artic Ser 14, 1–28 
Anderson RH, Webb S, Brown NA, Lamers W, Moorman A (2003): Development of the heart: (2) 
Septation of the atriums and ventricles. Heart 89, 949–958 
Atz AM, Feinstein JA, Jonas RA, Perry SB, Wessel DL (1999): Preoperative management of 
pulmonary venous hypertension in hypoplastic left heart syndrome with restrictive atrial 
septal defect. Am J Cardiol 83, 1224–1228 
Bailey LL (2004): Transplantation is the best treatment for hypoplastic left heart syndrome. Cardiol 
Young 14 Suppl 1, 109–111; discussion 112-114 
Bailey LL, Nehlsen-Cannarella SL, Concepcion W, Jolley WB (1985): Baboon-to-human cardiac 
xenotransplantation in a neonate. JAMA 254, 3321–3329 
Barnea O, Austin EH, Richman B, Santamore WP (1994): Balancing the circulation: theoretic 
optimization of pulmonary/systemic flow ratio in hypoplastic left heart syndrome. J Am 
Coll Cardiol 24, 1376–1381 
Bartman T, Hove J (2005): Mechanics and function in heart morphogenesis. Dev Dyn 233, 373–
381 
Bashaw GJ, Kidd T, Murray D, Pawson T, Goodman CS (2000): Repulsive axon guidance: Abelson 
and Enabled play opposing roles downstream of the roundabout receptor. Cell 101, 703–
715 
Behrendt DM, Rocchini A (1981): An operation for the hypoplastic left heart syndrome: 
preliminary report. Ann Thorac Surg 32, 284–288 
Beroukhim RS, Gauvreau K, Benavidez OJ, Baird CW, LaFranchi T, Tworetzky W (2015): 
Perinatal outcome after prenatal diagnosis of single-ventricle cardiac defects. Ultrasound 
Obstet Gynecol 45, 657–663 
Bharati S, Lev M (1984): The surgical anatomy of hypoplasia of aortic tract complex. J Thorac 
Cardiovasc Surg 88, 97–101 
6 List of references 74 
Blausen BE, Johannes RS, Hutchins GM (1990): Computer-based reconstructions of the cardiac 
ventricles of human embryos. Am J Cardiovasc Pathol 3, 37–43 
Boughman JA, Berg KA, Astemborski JA, Clark EB, McCarter RJ, Rubin JD, Ferencz C (1987): 
Familial risks of congenital heart defect assessed in a population-based epidemiologic 
study. Am J Med Genet 26, 839–849 
Bradley SM (1999): Neonatal repair and dealing with a single ventricle. J S C Med Assoc 95, 335–
338 
Bravo-Valenzuela NJ, Peixoto AB, Araujo Júnior E (2018): Prenatal diagnosis of congenital heart 
disease: A review of current knowledge. Indian Heart J 70, 150–164 
Brenner JI, Berg KA, Schneider DS, Clark EB, Boughman JA (1989): Cardiac malformations in 
relatives of infants with hypoplastic left-heart syndrome. Am J Dis Child 143, 1492–1494 
Captur G, Wilson R, Bennett MF, Luxán G, Nasis A, de la Pompa JL, Moon JC, Mohun TJ (2016): 
Morphogenesis of myocardial trabeculae in the mouse embryo. J Anat 229, 314–325 
Cassidy AR, White MT, DeMaso DR, Newburger JW, Bellinger DC (2015): Executive Function in 
Children and Adolescents with Critical Cyanotic Congenital Heart Disease. J Int 
Neuropsychol Soc 21, 34–49 
Chai P, Tian J, Zhao D, Zhang H, Cui J, Ding K, Liu B (2016): GSE1 negative regulation by miR-
489-5p promotes breast cancer cell proliferation and invasion. Biochem Biophys Res 
Commun 471, 123–128 
Chang AC, Huhta JC, Yoon GY, Wood DC, Tulzer G, Cohen A, Mennuti M, Norwood WI (1991): 
Diagnosis, transport, and outcome in fetuses with left ventricular outflow tract obstruction. 
J Thorac Cardiovasc Surg 102, 841–848 
Chen H, Shi S, Acosta L, Li W, Lu J, Bao S, Chen Z, Yang Z, Schneider MD, Chien KR, et al. 
(2004): BMP10 is essential for maintaining cardiac growth during murine cardiogenesis. 
Development 131, 2219–2231 
Chen Q, Tulloh R, Caputo M, Stoica S, Kia M, Parry AJ (2015): Does the persistence of pulsatile 
antegrade pulmonary blood flow following bidirectional Glenn procedure affect long term 
outcome? Eur J Cardiothorac Surg 47, 154–158; discussion 158 
Choquet C, Nguyen THM, Sicard P, Buttigieg E, Tran TT, Kober F, Varlet I, Sturny R, Costa MW, 
Harvey RP, et al. (2018): Deletion of Nkx2-5 in trabecular myocardium reveals the 
developmental origins of pathological heterogeneity associated with ventricular non-
compaction cardiomyopathy. PLoS Genet 14, e1007502 
Chrisant MRK, Naftel DC, Drummond-Webb J, Chinnock R, Canter CE, Boucek MM, Boucek RJ, 
Hallowell SC, Kirklin JK, Morrow WR, Pediatric Heart Transplant Study Group (2005): 
Fate of infants with hypoplastic left heart syndrome listed for cardiac transplantation: a 
multicenter study. J Heart Lung Transplant 24, 576–582 
Christoffels VM, Habets PE, Franco D, Campione M, de Jong F, Lamers WH, Bao ZZ, Palmer S, 
Biben C, Harvey RP, Moorman AF (2000): Chamber formation and morphogenesis in the 
developing mammalian heart. Dev Biol 223, 266–278 
Connor JA, Thiagarajan R (2007): Hypoplastic left heart syndrome. Orphanet J Rare Dis 2, 23 
Consevage MW, Seip JR, Belchis DA, Davis AT, Baylen BG, Rogan PK (1996): Association of a 
mosaic chromosomal 22q11 deletion with hypoplastic left heart syndrome. Am J Cardiol 
77, 1023–1025 
6 List of references 75 
Cox H, Wilson DI (2007): Genetics of hypoplastic left heart syndrome. Fetal Matern Med Rev 18, 
103–119 
Crucean A, Alqahtani A, Barron DJ, Brawn WJ, Richardson RV, O’Sullivan J, Anderson RH, 
Henderson DJ, Chaudhry B (2017): Re-evaluation of hypoplastic left heart syndrome from 
a developmental and morphological perspective. Orphanet J Rare Dis 12, 138 
Daebritz SH, Nollert GD, Zurakowski D, Khalil PN, Lang P, del Nido PJ, Mayer JE, Jonas RA 
(2000): Results of Norwood stage I operation: comparison of hypoplastic left heart 
syndrome with other malformations. J Thorac Cardiovasc Surg 119, 358–367 
Danford DA, Cronican P (1992): Hypoplastic left heart syndrome: progression of left ventricular 
dilation and dysfunction to left ventricular hypoplasia in utero. Am Heart J 123, 1712–1713 
Dasgupta C, Martinez AM, Zuppan CW, Shah MM, Bailey LL, Fletcher WH (2001): Identification 
of connexin43 (alpha1) gap junction gene mutations in patients with hypoplastic left heart 
syndrome by denaturing gradient gel electrophoresis (DGGE). Mutat Res 479, 173–186 
de Jong F, Opthof T, Wilde AA, Janse MJ, Charles R, Lamers WH, Moorman AF (1992): Persisting 
zones of slow impulse conduction in developing chicken hearts. Circ Res 71, 240–250 
de la Cruz MV, Sánchez-Gómez C, Palomino MA (1989): The primitive cardiac regions in the 
straight tube heart (Stage 9) and their anatomical expression in the mature heart: An 
experimental study in the chick embryo. J Anat 165, 121–131 
Deely WJ, Ehlers KH, Levin AR, Engle MA (1971): Hypoplastic left heart syndrome. Anatomic, 
physiologic, and therapeutic consideraons. Am J Dis Child 121, 168–175 
Dhanantwari P, Lee E, Krishnan A, Samtani R, Yamada S, Anderson S, Lockett E, Donofrio M, 
Shiota K, Leatherbury L, Lo CW (2009): Human cardiac development in the first trimester: 
a high-resolution magnetic resonance imaging and episcopic fluorescence image capture 
atlas. Circulation 120, 343–351, figure 6, p.343 
Dodou E, Verzi MP, Anderson JP, Xu S-M, Black BL (2004): Mef2c is a direct transcriptional 
target of ISL1 and GATA factors in the anterior heart field during mouse embryonic 
development. Development 131, 3931–3942 
Donofrio MT, Skurow-Todd K, Berger JT, McCarter R, Fulgium A, Krishnan A, Sable CA (2015): 
Risk-stratified postnatal care of newborns with congenital heart disease determined by fetal 
echocardiography. J Am Soc Echocardiogr 28, 1339–1349 
Doty DB, Knott HW (1977): Hypoplastic left heart syndrome. Experience with an operation to 
establish functionally normal circulation. J Thorac Cardiovasc Surg 74, 624–630 
Dyer LA, Kirby ML (2009): The role of secondary heart field in cardiac development. Dev Biol 
336, 137–144 
Eisenberg LM, Markwald RR (1995): Molecular regulation of atrioventricular valvuloseptal 
morphogenesis. Circ Res 77, 1–6 
Elliott MJ (2004): A European perspective on the management of hypoplastic left heart syndrome. 
Cardiol Young 14 Suppl 1, 41–46 
Feinstein JA, Benson DW, Dubin AM, Cohen MS, Maxey DM, Mahle WT, Pahl E, Villafañe J, 
Bhatt AB, Peng LF, et al. (2012): Hypoplastic left heart syndrome: current considerations 
and expectations. J Am Coll Cardiol 59, S1-42 
6 List of references 76 
Ferencz C, Rubin JD, McCarter RJ, Brenner JI, Neill CA, Perry LW, Hepner SI, Downing JW 
(1985): Congenital heart disease: prevalence at livebirth. The Baltimore-Washington Infant 
Study. Am J Epidemiol 121, 31–36 
Fontan F, Baudet E (1971): Surgical repair of tricuspid atresia. Thorax 26, 240–248 
Freedom RM, Dische MR, Rowe RD (1977): Conal anatomy in aortic atresia, ventricular septal 
defect, and normally developed left ventricle. Am Heart J 94, 689–698 
Freud LR, McElhinney DB, Marshall AC, Marx GR, Friedman KG, del Nido PJ, Emani SM, 
Lafranchi T, Silva V, Wilkins-Haug LE, et al. (2014): Fetal aortic valvuloplasty for evolving 
hypoplastic left heart syndrome: postnatal outcomes of the first 100 patients. Circulation 
130, 638–645 
Friehs I, Illigens B, Melnychenko I, Zhong-Hu T, Zeisberg E, Del Nido PJ (2013): An animal 
model of endocardial fibroelastosis. J Surg Res 182, 94–100 
Frommelt PC, Sheridan DC, Mussatto KA, Hoffman GM, Ghanayem NS, Frommelt MA, 
Tweddell JS (2007): Effect of shunt type on echocardiographic indices after initial 
palliations for hypoplastic left heart syndrome: Blalock-Taussig shunt versus right 
ventricle-pulmonary artery conduit. J Am Soc Echocardiogr 20, 1364–1373 
Galantowicz M, Cheatham JP (2005): Lessons learned from the development of a new hybrid 
strategy for the management of hypoplastic left heart syndrome. Pediatr Cardiol 26, 190–
199 
Gassmann M, Casagranda F, Orioli D, Simon H, Lai C, Klein R, Lemke G (1995): Aberrant neural 
and cardiac development in mice lacking the ErbB4 neuregulin receptor. Nature 378, 390–
394 
Gehrmann J, Krasemann T, Kehl HG, Vogt J (2001): Hypoplastic left-heart syndrome: the first 
description of the pathophysiology in 1851; translation of a publication by Dr. Bardeleben 
from Giessen, Germany. Chest 120, 1368–1371 
Gillum RF (1994): Epidemiology of congenital heart disease in the United States. Am Heart J 127, 
919–927 
Gittenberger-de Groot AC, Bartelings MM, Deruiter MC, Poelmann RE (2005): Basics of cardiac 
development for the understanding of congenital heart malformations. Pediatr Res 57, 
169–176 
Glenn WW (1958): Circulatory bypass of the right side of the heart. IV. Shunt between superior 
vena cava and distal right pulmonary artery; report of clinical application. N Engl J Med 
259, 117–120 
Gong H, Lyu X, Wang Q, Hu M, Zhang X (2017): Endothelial to mesenchymal transition in the 
cardiovascular system. Life Sci 184, 95–102 
Gossler A, Joyner AL, Rossant J, Skarnes WC (1989): Mouse embryonic stem cells and reporter 
constructs to detect developmentally regulated genes. Science 244, 463–465 
Graupner O, Enzensberger C, Wieg L, Degenhardt J, Wolter A, Khalil M, Schranz D, Yerebakan 
C, Doelle A, Herrmann J, Axt-Fliedner R (2018): Endocardial Fibroelastosis of the Left 
Ventricle Affects Right Ventricular Performance in Fetuses with Hypoplastic Left Heart 
Syndrome: A Prospective Study Using M-Mode, PW- and Tissue Doppler Techniques. 
Ultraschall Med 39, 413–421 
6 List of references 77 
Grossfeld PD, Mattina T, Lai Z, Favier R, Jones KL, Cotter F, Jones C (2004): The 11q terminal 
deletion disorder: a prospective study of 110 cases. Am J Med Genet A 129A, 51–61 
Hakimi M-A, Dong Y, Lane WS, Speicher DW, Shiekhattar R (2003): A candidate X-linked mental 
retardation gene is a component of a new family of histone deacetylase-containing 
complexes. J Biol Chem 278, 7234–7239 
Hastreiter AR, Van der Horst RL, Dubrow IW, Eckner FO (1983): Quantitative angiographic and 
morphologic aspects of aortic valve atresia. Am J Cardiol 51, 1705–1708 
Hebra A, Brown MF, Hirschl RB, McGeehin K, O’Neill JA, Norwood WI, Ross AJ (1993): 
Mesenteric ischemia in hypoplastic left heart syndrome. J Pediatr Surg 28, 606–611 
Hellmund A, Berg C, Herberg U, Geipel A, Kempe A, Gembruch U (2017): Levoatrial Cardinal 
Vein in a Series of Five Prenatal Cases with Hypoplastic Left Heart Syndrome and Intact 
Atrial Septum. Ultraschall Med 38, 206–211 
Hinton RB, Benson DW: Hypoplastic Left Heart Syndrome; In: Moller JH, Hoffman JIE (Eds.): 
Pediatric Cardiovascular Medicine, 2nd Edition; John Wiley & Sons, Chichester 2012, 523–
533 
Hinton RB, Martin LJ, Tabangin ME, Mazwi ML, Cripe LH, Benson DW (2007): Hypoplastic left 
heart syndrome is heritable. J Am Coll Cardiol 50, 1590–1595 
Hinton RB, Martin LJ, Rame-Gowda S, Tabangin ME, Cripe LH, Benson DW (2009): Hypoplastic 
left heart syndrome links to chromosomes 10q and 6q and is genetically related to bicuspid 
aortic valve. J Am Coll Cardiol 53, 1065–1071 
Hu N, Sedmera D, Yost HJ, Clark EB (2000): Structure and function of the developing zebrafish 
heart. Anat Rec 260, 148–157 
Huang W-H, Sung K-T, Tsai J-P, Lo C-I, Hsiao C-C, Kuo J-Y, Su C-H, Chen M-R, Hung C-L 
(2018): Clinical and Echocardiography Features of Diagnosed in Adulthood Isolated Left 
Ventricular Noncompaction: A Case Series Study. J Med Ultrasound 26, 37–41 
Iascone M, Ciccone R, Galletti L, Marchetti D, Seddio F, Lincesso AR, Pezzoli L, Vetro A, 
Barachetti D, Boni L, et al. (2012): Identification of de novo mutations and rare variants in 
hypoplastic left heart syndrome. Clin Genet 81, 542–554 
Ishii Y, Inamura N, Kayatani F, Iwai S, Kawata H, Arakawa H, Kishimoto H (2014): Evaluation of 
bilateral pulmonary artery banding for initial palliation in single-ventricle neonates and 
infants: risk factors for mortality before the bidirectional Glenn procedure. Interact 
Cardiovasc Thorac Surg 19, 807–811 
Jacobs ML, Blackstone EH, Bailey LL (1998): Intermediate survival in neonates with aortic atresia: 
a multi-institutional study. The Congenital Heart Surgeons Society. J Thorac Cardiovasc 
Surg 116, 417–431 
Jenni R, Oechslin EN, van der Loo B (2007): Isolated ventricular non-compaction of the 
myocardium in adults. Heart 93, 11–15 
Johnson BA, Mussatto K, Uhing MR, Zimmerman H, Tweddell J, Ghanayem N (2008): Variability 
in the preoperative management of infants with hypoplastic left heart syndrome. Pediatr 
Cardiol 29, 515–520 
Kanjuh V, Eliot RS, Edwards JE (1965): Coexistent mitral and aortic valvular atresia: a pathologic 
study of 14 cases. Am J Cardiol 15, 611–621 
6 List of references 78 
Kelly RG, Buckingham ME (2002): The anterior heart-forming field: voyage to the arterial pole of 
the heart. Trends Genet 18, 210–216 
Kenchegowda D, Liu H, Thompson K, Luo L, Martin SS, Fisher SA (2014): Vulnerability of the 
developing heart to oxygen deprivation as a cause of congenital heart defects. J Am Heart 
Assoc 3, e000841 
Kern JH, Hayes CJ, Michler RE, Gersony WM, Quaegebeur JM (1997): Survival and risk factor 
analysis for the Norwood procedure for hypoplastic left heart syndrome. Am J Cardiol 80, 
170–174 
Kim KH, Nakaoka Y, Augustin HG, Koh GY (2018): Myocardial Angiopoietin-1 Controls Atrial 
Chamber Morphogenesis by Spatiotemporal Degradation of Cardiac Jelly. Cell Rep 23, 
2455–2466 
Kinsella MG, Fitzharris TP (1980): Origin of cushion tissue in the developing chick heart: 
cinematographic recordings of in situ formation. Science 207, 1359–1360 
Knott HW, Doty DB (1977): Experimental bypass of the left ventricle. J Thorac Cardiovasc Surg 
74, 436–439 
Kokoszka JE, Waymire KG, Flierl A, Sweeney KM, Angelin A, MacGregor GR, Wallace DC 
(2016): Deficiency in the mouse mitochondrial adenine nucleotide translocator isoform 2 
gene is associated with cardiac noncompaction. Biochim Biophys Acta 1857, 1203–1212 
Kreidberg JA, Sariola H, Loring JM, Maeda M, Pelletier J, Housman D, Jaenisch R (1993): WT-1 is 
required for early kidney development. Cell 74, 679–691 
Krenning G, Zeisberg EM, Kalluri R (2010): The origin of fibroblasts and mechanism of cardiac 
fibrosis. J Cell Physiol 225, 631–637 
Krishnan A, Samtani R, Dhanantwari P, Lee E, Yamada S, Shiota K, Donofrio MT, Leatherbury L, 
Lo CW (2014): A detailed comparison of mouse and human cardiac development. Pediatr 
Res 76, 500–507 
Lamers WH, Moorman AFM (2002): Cardiac septation: a late contribution of the embryonic 
primary myocardium to heart morphogenesis. Circ Res 91, 93–103 
Landi D, Gemignani F, Pardini B, Naccarati A, Garritano S, Vodicka P, Vodickova L, Canzian F, 
Novotny J, Barale R, Landi S (2012): Identification of candidate genes carrying 
polymorphisms associated with the risk of colorectal cancer by analyzing the colorectal 
mutome and microRNAome. Cancer 118, 4670–4680 
Lee KF, Simon H, Chen H, Bates B, Hung MC, Hauser C (1995): Requirement for neuregulin 
receptor erbB2 in neural and cardiac development. Nature 378, 394–398 
Lev M (1952): Pathologic anatomy and interrelationship of hypoplasia of the aortic tract complexes. 
Lab Invest 1, 61–70 
Li J, Zhang G, McCrindle BW, Holtby H, Humpl T, Cai S, Caldarone CA, Redington AN, Van 
Arsdell GS (2007): Profiles of hemodynamics and oxygen transport derived by using 
continuous measured oxygen consumption after the Norwood procedure. J Thorac 
Cardiovasc Surg 133, 441–448 
Li Y-Y, Zhang J-P (2006): Gene trapping techniques and current progress. Yi Chuan Xue Bao 33, 
189–198 
6 List of references 79 
Liao W, Bisgrove BW, Sawyer H, Hug B, Bell B, Peters K, Grunwald DJ, Stainier DY (1997): The 
zebrafish gene cloche acts upstream of a flk-1 homologue to regulate endothelial cell 
differentiation. Development 124, 381–389 
Lin F, Wang N, Zhang T-C (2012): The role of endothelial-mesenchymal transition in development 
and pathological process. IUBMB Life 64, 717–723 
Lin Q, Schwarz J, Bucana C, Olson EN (1997): Control of mouse cardiac morphogenesis and 
myogenesis by transcription factor MEF2C. Science 276, 1404–1407 
Lin Y, Wu Y, Li J, Dong C, Ye X, Chi Y-I, Evers BM, Zhou BP (2010): The SNAG domain of 
Snail1 functions as a molecular hook for recruiting lysine-specific demethylase 1. EMBO J 
29, 1803–1816 
Linask KK, Yu X, Chen Y, Han M-D (2002): Directionality of heart looping: effects of Pitx2c 
misexpression on flectin asymmetry and midline structures. Dev Biol 246, 407–417 
Lloyd TR, Evans TC, Marvin WJ (1986): Morphologic determinants of coronary blood flow in the 
hypoplastic left heart syndrome. Am Heart J 112, 666–671 
Loffredo CA, Chokkalingam A, Sill AM, Boughman JA, Clark EB, Scheel J, Brenner JI (2004): 
Prevalence of congenital cardiovascular malformations among relatives of infants with 
hypoplastic left heart, coarctation of the aorta, and d-transposition of the great arteries. Am 
J Med Genet A 124A, 225–230 
Lurie PR (2010): Changing concepts of endocardial fibroelastosis. Cardiol Young 20, 115–123 
Luxán G, D’Amato G, MacGrogan D, de la Pompa JL (2016): Endocardial Notch Signaling in 
Cardiac Development and Disease. Circ Res 118, e1–e18 
Lyons I, Parsons LM, Hartley L, Li R, Andrews JE, Robb L, Harvey RP (1995): Myogenic and 
morphogenetic defects in the heart tubes of murine embryos lacking the homeo box gene 
Nkx2-5. Genes Dev 9, 1654–1666 
Mahowald JM, Lucas RV, Edwards JE (1982): Aortic valvular atresia. Associated cardiovascular 
anomalies. Pediatr Cardiol 2, 99–105 
Mäkikallio K, McElhinney DB, Levine JC, Marx GR, Colan SD, Marshall AC, Lock JE, Marcus 
EN, Tworetzky W (2006): Fetal aortic valve stenosis and the evolution of hypoplastic left 
heart syndrome: patient selection for fetal intervention. Circulation 113, 1401–1405 
Maxwell D, Allan L, Tynan MJ (1991): Balloon dilatation of the aortic valve in the fetus: a report of 
two cases. Br Heart J 65, 256–258 
McElhinney DB, Marshall AC, Wilkins-Haug LE, Brown DW, Benson CB, Silva V, Marx GR, 
Mizrahi-Arnaud A, Lock JE, Tworetzky W (2009): Predictors of technical success and 
postnatal biventricular outcome after in utero aortic valvuloplasty for aortic stenosis with 
evolving hypoplastic left heart syndrome. Circulation 120, 1482–1490 
Meilhac SM, Esner M, Kelly RG, Nicolas J-F, Buckingham ME (2004): The clonal origin of 
myocardial cells in different regions of the embryonic mouse heart. Dev Cell 6, 685–698 
Memczak S, Jens M, Elefsinioti A, Torti F, Krueger J, Rybak A, Maier L, Mackowiak SD, 
Gregersen LH, Munschauer M, et al. (2013): Circular RNAs are a large class of animal 
RNAs with regulatory potency. Nature 495, 333–338 
Meyer D, Birchmeier C (1995): Multiple essential functions of neuregulin in development. Nature 
378, 386–390 
6 List of references 80 
Miquerol L, Gertsenstein M, Harpal K, Rossant J, Nagy A (1999): Multiple developmental roles of 
VEGF suggested by a LacZ-tagged allele. Dev Biol 212, 307–322 
Moens CB, Stanton BR, Parada LF, Rossant J (1993): Defects in heart and lung development in 
compound heterozygotes for two different targeted mutations at the N-myc locus. 
Development 119, 485–499 
Moodie DS, Gallen WJ, Friedberg DZ (1972): Congenital aortic atresia. Report of long survival and 
some speculations about surgical approaches. J Thorac Cardiovasc Surg 63, 726–731 
Moorman A, Webb S, Brown NA, Lamers W, Anderson RH (2003): Development of the heart: (1) 
formation of the cardiac chambers and arterial trunks. Heart 89, 806–814 
Morris CD, Outcalt J, Menashe VD (1990): Hypoplastic left heart syndrome: natural history in a 
geographically defined population. Pediatrics 85, 977–983 
Mu TS, McAdams RM, Bush DM (2005): A case of hypoplastic left heart syndrome and bicuspid 
aortic valve in monochorionic twins. Pediatr Cardiol 26, 884–885 
Murphy MO, Bellsham-Revell H, Morgan GJ, Krasemann T, Rosenthal E, Qureshi SA, Salih C, 
Austin CB, Anderson DR (2015): Hybrid Procedure for Neonates With Hypoplastic Left 
Heart Syndrome at High-Risk for Norwood: Midterm Outcomes. Ann Thorac Surg 100, 
2286–2290; discussion 2291-2292 
Nagase T, Seki N, Ishikawa K, Tanaka A, Nomura N (1996): Prediction of the coding sequences of 
unidentified human genes. V. The coding sequences of 40 new genes (KIAA0161-
KIAA0200) deduced by analysis of cDNA clones from human cell line KG-1. DNA Res 3, 
17–24 
Natowicz M, Kelley RI (1987): Association of Turner syndrome with hypoplastic left-heart 
syndrome. Am J Dis Child 141, 218–220 
Natowicz M, Chatten J, Clancy R, Conard K, Glauser T, Huff D, Lin A, Norwood W, Rorke LB, 
Uri A (1988): Genetic disorders and major extracardiac anomalies associated with the 
hypoplastic left heart syndrome. Pediatrics 82, 698–706 
Nebigil CG, Choi DS, Dierich A, Hickel P, Le Meur M, Messaddeq N, Launay JM, Maroteaux L 
(2000): Serotonin 2B receptor is required for heart development. Proc Natl Acad Sci USA 
97, 9508–9513 
Noonan JA, Nadas AS (1958): The hypoplastic left heart syndrome; an analysis of 101 cases. 
Pediatr Clin North Am 5, 1029–1056 
Norwood WI, Lang P, Hansen DD (1983): Physiologic repair of aortic atresia-hypoplastic left heart 
syndrome. N Engl J Med 308, 23–26 
Person AD, Klewer SE, Runyan RB (2005): Cell biology of cardiac cushion development. Int Rev 
Cytol 243, 287–335 
Pignatelli RH, McMahon CJ, Dreyer WJ, Denfield SW, Price J, Belmont JW, Craigen WJ, Wu J, El 
Said H, Bezold LI, et al. (2003): Clinical characterization of left ventricular noncompaction 
in children: a relatively common form of cardiomyopathy. Circulation 108, 2672–2678 
Poelmann RE, Gittenberger-de Groot AC (2018): Hemodynamics in Cardiac Development. J 
Cardiovasc Dev Dis 5, 54–73 
6 List of references 81 
Pradat P, Francannet C, Harris JA, Robert E (2003): The epidemiology of cardiovascular defects, 
part I: a study based on data from three large registries of congenital malformations. 
Pediatr Cardiol 24, 195–221 
Pruetz JD, Carroll C, Trento LU, Chang R-K, Detterich J, Miller DA, Sklansky M (2014): 
Outcomes of critical congenital heart disease requiring emergent neonatal cardiac 
intervention. Prenat Diagn 34, 1127–1132 
Pundi KN, Johnson JN, Dearani JA, Pundi KN, Li Z, Hinck CA, Dahl SH, Cannon BC, O’Leary 
PW, Driscoll DJ, Cetta F (2015): 40-Year Follow-Up After the Fontan Operation: Long-
Term Outcomes of 1,052 Patients. J Am Coll Cardiol 66, 1700–1710 
Puri MC, Partanen J, Rossant J, Bernstein A (1999): Interaction of the TEK and TIE receptor 
tyrosine kinases during cardiovascular development. Development 126, 4569–4580 
Quéméner-Redon S, Bénech C, Audebert-Bellanger S, Friocourt G, Planes M, Parent P, Férec C 
(2013): A small de novo 16q24.1 duplication in a woman with severe clinical features. Eur J 
Med Genet 56, 211–215 
Ramamoorthy C, Tabbutt S, Kurth CD, Steven JM, Montenegro LM, Durning S, Wernovsky G, 
Gaynor JW, Spray TL, Nicolson SC (2002): Effects of inspired hypoxic and hypercapnic 
gas mixtures on cerebral oxygen saturation in neonates with univentricular heart defects. 
Anesthesiology 96, 283–288 
Risebro CA, Riley PR (2006): Formation of the ventricles. ScientificWorldJournal 6, 1862–1880 
Roberts WC, Perry LW, Chandra RS, Myers GE, Shapiro SR, Scott LP (1976): Aortic valve atresia: 
a new classification based on necropsy study of 73 cases. Am J Cardiol 37, 753–756 
Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, Carnethon MR, Dai S, de 
Simone G, Ford ES, et al. (2011): Heart disease and stroke statistics--2011 update: a report 
from the American Heart Association. Circulation 123, e18–e209 
Rychik J, Rome JJ, Collins MH, DeCampli WM, Spray TL (1999): The hypoplastic left heart 
syndrome with intact atrial septum: atrial morphology, pulmonary vascular histopathology 
and outcome. J Am Coll Cardiol 34, 554–560 
Ryder E, Doe B, Gleeson D, Houghton R, Dalvi P, Grau E, Habib B, Miklejewska E, Newman S, 
Sethi D, et al. (2014): Rapid conversion of EUCOMM/KOMP-CSD alleles in mouse 
embryos using a cell-permeable Cre recombinase. Transgenic Res 23, 177–185 
Samánek M, Benesová D, Goetzová J, Hrycejová I (1988): Distribution of age at death in children 
with congenital heart disease who died before the age of 15. Br Heart J 59, 581–585 
Sanapo L, Pruetz JD, Słodki M, Goens MB, Moon-Grady AJ, Donofrio MT (2017): Fetal 
echocardiography for planning perinatal and delivery room care of neonates with 
congenital heart disease. Echocardiography 34, 1804–1821 
Sato TN, Tozawa Y, Deutsch U, Wolburg-Buchholz K, Fujiwara Y, Gendron-Maguire M, Gridley 
T, Wolburg H, Risau W, Qin Y (1995): Distinct roles of the receptor tyrosine kinases Tie-1 
and Tie-2 in blood vessel formation. Nature 376, 70–74 
Sawai S, Shimono A, Wakamatsu Y, Palmes C, Hanaoka K, Kondoh H (1993): Defects of 
embryonic organogenesis resulting from targeted disruption of the N-myc gene in the 
mouse. Development 117, 1445–1455 
Sedmera D, Thomas PS (1996): Trabeculation in the embryonic heart. Bioessays 18, 607–607 
6 List of references 82 
Sedmera D, Hu N, Weiss KM, Keller BB, Denslow S, Thompson RP (2002): Cellular changes in 
experimental left heart hypoplasia. Anat Rec 267, 137–145 
Selamet Tierney ES, Wald RM, McElhinney DB, Marshall AC, Benson CB, Colan SD, Marcus EN, 
Marx GR, Levine JC, Wilkins-Haug L, et al. (2007): Changes in left heart hemodynamics 
after technically successful in-utero aortic valvuloplasty. Ultrasound Obstet Gynecol 30, 
715–720 
Shimada S, Robles C, Illigens BMW, Casar Berazaluce AM, del Nido PJ, Friehs I (2015): Distention 
of the Immature Left Ventricle Triggers Development of Endocardial Fibroelastosis: An 
Animal Model of Endocardial Fibroelastosis Introducing Morphopathological Features of 
Evolving Fetal Hypoplastic Left Heart Syndrome. Biomed Res Int 2015, 462-469 
Shime N, Hashimoto S, Hiramatsu N, Oka T, Kageyama K, Tanaka Y (2000): Hypoxic gas therapy 
using nitrogen in the preoperative management of neonates with hypoplastic left heart 
syndrome. Pediatr Crit Care Med 1, 38–41 
Silva JP da, Fonseca L da, Baumgratz JF, Castro RM, Franchi SM, Lianza AC, Vila JHA (2007): 
Hypoplastic left heart syndrome: the report of a surgical strategy and comparative results 
of Norwood x Norwood-Sano approach. Rev Bras Cir Cardiovasc 22, 160–168 
Sinha SN, Rusnak SL, Sommers HM, Cole RB, Muster AJ, Paul MH (1968): Hypoplastic left 
ventricle syndrome. Analysis of thirty autopsy cases in infants with surgical considerations. 
Am J Cardiol 21, 166–173 
Skarnes WC, Rosen B, West AP, Koutsourakis M, Bushell W, Iyer V, Mujica AO, Thomas M, 
Harrow J, Cox T, et al. (2011): A conditional knockout resource for the genome-wide study 
of mouse gene function. Nature 474, 337–342 
Sokolowski L, Respondek-Liberska M, Pietryga M, Slodki M (2019): Prenatally diagnosed foramen 
ovale restriction in fetuses with hypoplastic left heart syndrome may be a predictor of 
longer hospitalization, but not of a need for an urgent rashkind procedure. Ginekol Pol 90, 
31–38 
Srivastava D, Thomas T, Lin Q, Kirby ML, Brown D, Olson EN (1997): Regulation of cardiac 
mesodermal and neural crest development by the bHLH transcription factor, dHAND. 
Nat Genet 16, 154–160 
Stainier DY, Weinstein BM, Detrich HW, Zon LI, Fishman MC (1995): Cloche, an early acting 
zebrafish gene, is required by both the endothelial and hematopoietic lineages. 
Development 121, 3141–3150 
Stallmeyer B, Fenge H, Nowak-Göttl U, Schulze-Bahr E (2010): Mutational spectrum in the cardiac 
transcription factor gene NKX2.5 (CSX) associated with congenital heart disease. Clin 
Genet 78, 533–540 
Stalsberg H (1969): The origin of heart asymmetry: right and left contributions to the early chick 
embryo heart. Dev Biol 19, 109–127 
Stanford WL, Cohn JB, Cordes SP (2001): Gene-trap mutagenesis: past, present and beyond. Nat 
Rev Genet 2, 756–768 
Stieh J, Fischer G, Scheewe J, Uebing A, Dütschke P, Jung O, Grabitz R, Trampisch HJ, Kramer 
HH (2006): Impact of preoperative treatment strategies on the early perioperative outcome 
in neonates with hypoplastic left heart syndrome. J Thorac Cardiovasc Surg 131, 1122–
1129 
6 List of references 83 
Stümpflen I, Stümpflen A, Wimmer M, Bernaschek G (1996): Effect of detailed fetal 
echocardiography as part of routine prenatal ultrasonographic screening on detection of 
congenital heart disease. Lancet 348, 854–857 
Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC, Davis S, Sato TN, Yancopoulos GD 
(1996): Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic 
angiogenesis. Cell 87, 1171–1180 
Tabbutt S, Ramamoorthy C, Montenegro LM, Durning SM, Kurth CD, Steven JM, Godinez RI, 
Spray TL, Wernovsky G, Nicolson SC (2001): Impact of inspired gas mixtures on 
preoperative infants with hypoplastic left heart syndrome during controlled ventilation. 
Circulation 104, I159–164 
Tchervenkov CI, Jacobs JP, Weinberg PM, Aiello VD, Béland MJ, Colan SD, Elliott MJ, Franklin 
RCG, Gaynor JW, Krogmann ON, et al. (2006): The nomenclature, definition and 
classification of hypoplastic left heart syndrome. Cardiol Young 16, 339–368 
Tennstedt C, Chaoui R, Körner H, Dietel M (1999): Spectrum of congenital heart defects and 
extracardiac malformations associated with chromosomal abnormalities: results of a seven-
year necropsy study. Heart 82, 34–39 
Thiene G, Gallucci V, Macartney FJ, Del Torso S, Pellegrino PA, Anderson RH (1979): Anatomy 
of aortic atresia. Cases presenting with a ventricular septal defect. Circulation 59, 173–178 
Tola HT, Ergul Y, Saygi M, Ozyilmaz I, Guzeltas A, Odemis E (2015): Ductal stent implantation in 
tetralogy of fallot with aortic arch abnormality. Tex Heart Inst J 42, 281–284 
Toyofuku T, Zhang H, Kumanogoh A, Takegahara N, Yabuki M, Harada K, Hori M, Kikutani H 
(2004): Guidance of myocardial patterning in cardiac development by Sema6D reverse 
signalling. Nat Cell Biol 6, 1204–1211 
Tworetzky W, McElhinney DB, Reddy VM, Brook MM, Hanley FL, Silverman NH (2001): 
Improved surgical outcome after fetal diagnosis of hypoplastic left heart syndrome. 
Circulation 103, 1269–1273 
Verzi MP, McCulley DJ, De Val S, Dodou E, Black BL (2005): The right ventricle, outflow tract, 
and ventricular septum comprise a restricted expression domain within the 
secondary/anterior heart field. Dev Biol 287, 134–145 
Vlahos AP, Lock JE, McElhinney DB, van der Velde ME (2004): Hypoplastic left heart syndrome 
with intact or highly restrictive atrial septum: outcome after neonatal transcatheter atrial 
septostomy. Circulation 109, 2326–2330 
Vogel M, Wilkins-Haug LE, McElhinney DB, Marshall AC, Benson CB, Silva V, Tworetzky W 
(2010): Reversible ductus arteriosus constriction due to maternal indomethacin after fetal 
intervention for hypoplastic left heart syndrome with intact/restrictive atrial septum. Fetal 
Diagn Ther 27, 40–45 
von Both I, Silvestri C, Erdemir T, Lickert H, Walls JR, Henkelman RM, Rossant J, Harvey RP, 
Attisano L, Wrana JL (2004): Foxh1 is essential for development of the anterior heart field. 
Dev Cell 7, 331–345 
von Rueden TJ, Knight L, Moller JH, Ewards JE (1975): Coarctation of the aorta associated with 
aortic valvular atresia. Circulation 52, 951–954 
Waller BF, Smith ER, Blackbourne BD, Arce FP, Sarkar NN, Roberts WC (1980): Congenital 
hypoplasia of portions of both right and left ventricular myocardial walls. Clinical and 
6 List of references 84 
necropsy observations in two patients with parchment heart syndrome. Am J Cardiol 46, 
885–891 
Watson DG, Rowe RD (1962): Aortic-valve atresia. Report of 43 cases. JAMA 179, 14–18 
Webb S, Brown NA, Anderson RH (1996): The structure of the mouse heart in late fetal stages. 
Anat Embryol 194, 37–47 
Weinberg PM, Chin AJ, Murphy JD, Pigott JD, Norwood WI (1986): Postmortem 
echocardiography and tomographic anatomy of hypoplastic left heart syndrome after 
palliative surgery. Am J Cardiol 58, 1228–1232 
Wessels A, Sedmera D (2003): Developmental anatomy of the heart: a tale of mice and man. 
Physiol Genomics 15, 165–176 
Wilson WM, Valente AM, Hickey EJ, Clift P, Burchill L, Emmanuel Y, Gibson P, Greutmann M, 
Grewal J, Grigg LE, et al. (2018): Outcomes of Patients With Hypoplastic Left Heart 
Syndrome Reaching Adulthood After Fontan Palliation: Multicenter Study. Circulation 
137, 978–981 
Xu X, Friehs I, Zhong Hu T, Melnychenko I, Tampe B, Alnour F, Iascone M, Kalluri R, Zeisberg 
M, Del Nido PJ, Zeisberg EM (2015): Endocardial fibroelastosis is caused by aberrant 
endothelial to mesenchymal transition. Circ Res 116, 857–866 
Yang P, Wang Y, Chen J, Li H, Kang L, Zhang Y, Chen S, Zhu B, Gao S (2011): RCOR2 is a 
subunit of the LSD1 complex that regulates ESC property and substitutes for SOX2 in 
reprogramming somatic cells to pluripotency. Stem Cells 29, 791–801 
Yokoyama A, Takezawa S, Schüle R, Kitagawa H, Kato S (2008): Transrepressive function of TLX 
requires the histone demethylase LSD1. Mol Cell Biol 28, 3995–4003 
Yun SW (2011): Congenital heart disease in the newborn requiring early intervention. Korean J 
Pediatr 54, 183–191 
Zeisberg EM, Kalluri R (2010): Origins of cardiac fibroblasts. Circ Res 107, 1304–1312 
Zhang J, Lin Y, Zhang Y, Lan Y, Lin C, Moon AM, Schwartz RJ, Martin JF, Wang F (2008): 
Frs2alpha-deficiency in cardiac progenitors disrupts a subset of FGF signals required for 
outflow tract morphogenesis. Development 135, 3611–3622 
Zhang W, Chen H, Qu X, Chang C-P, Shou W (2013): Molecular mechanism of ventricular 
trabeculation/compaction and the pathogenesis of the left ventricular noncompaction 












131149;r=16:85169525-85676204; accessed on April 19th, 2019 
ensembl.org/Mus_musculus/Gene/Phenotype  
http://www.ensembl.org/Mus_musculus/Gene/Phenotype?db=core;g=ENSMUSG0
0000031822;r=8:120228456-120581390; accessed on April 19th, 2019 
ensembl.org/Mus_musculus/Gene/TranscriptComparison 
http://www.ensembl.org/Mus_musculus/Gene/TranscriptComparison?db=core;g=E
NSMUSG00000031822;r=8:120228456-120581390; accessed on April 19th, 2019 
genecards.org  
https://www.genecards.org/cgi-bin/carddisp.pl?gene=GSE1; accessed on April 19th, 
2019 
genome.gov 
https://www.genome.gov/human-genome-project/What; accessed on April 19th, 
2019 
knockoutmouse.org 
http://www.knockoutmouse.org/martsearch/project/71610; accessed on April 19th, 
2019 
mousephenotype.org 
https://www.mousephenotype.org/about-impc/about-ikmc/eucomm/; accessed on 
April 19th, 2019 
ncbi.nlm.nih.gov 
https://www.ncbi.nlm.nih.gov/gene/23199; accessed on April 19th, 2019 
  
 
 
 
 
  
